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Abstract
Despite the numerous advances in cancer therapy over the past 50 years, cancer
still remains the major cause of mortality worldwide, and thus new and more
efficient treatments are needed. Oncolytic viruses have shown promising results in
preclinical and clinical studies for the treatment of solid tumors, but their efficacy
often remains low.
A multitude of viral strains, such as adenovirus, have been engineered to become
tumor-selective and to stimulate the immune system against the tumors. Alteration
of viral surface proteins that recognize specific cellular receptors, modification of
viral genes required for viral replication and insertion of immunostimulatory
molecules in the viral genome are promising ways to allow the virus to specifically
enter and kill cancer cells by oncolysis, and to stimulate antitumoral immune
responses. One example of oncolytic virus featuring these three modifications is
Ad5/3-D24-GMCSF, a tumor-selective 5/3 chimeric oncolytic adenovirus armed
with the immunostimulatory granulocyte-macrophage colony-stimulating factor
(GM-CSF). In preclinical models, Ad5/3-D24-GMCSF has displayed good
antitumor efficacy, production of functional GM-CSF and tumor-selective
replication. Good tolerability, possible treatment benefits and activation of immune
responses have also been observed in cancer patients.
In this thesis, we studied the utility of Ad5/3-D24-GMCSF in the treatment of
sarcoma, melanoma and breast cancer. The data is promising with regard to future
clinical trials and for personalized cancer treatments.
The virus showed strong oncolytic potential in vitro and antitumor efficacy in
immunodeficient animal models. Furthermore, replication-linked GM-CSF
production stimulated the differentiation of human monocytes into macrophages,
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important for induction of antitumor immune responses. In immunocompetent
Syrian hamsters with soft-tissue sarcoma (STS) tumors, Ad5/3-D24-GMCSF
reached non-injected tumors through vascular circulation, suggesting its utility for
the treatment of metastatic disease.
Combination of Ad5/3-D24-GMCSF with chemotherapeutics that possess
immunogenic properties (doxorubicin and ifosfamide) and that selectively reduce
circulating regulatory T-cells (cyclophosphamide) was studied to enhance
antitumor efficacy. Our results showed that chemotherapeutic agents may have a
useful combination effect with the virus, due to enhancement of adenoviral
replication and induction of immunogenic cell death, setting the stage for clinical
testing of combination regimens.
Finally we reported safety and possible signs of efficacy in 40 patients with
advanced sarcoma, melanoma and breast cancer, who were treated in the context of
an Advanced Therapy Access Program (ATAP). Treatments were overall well-
tolerated, and objective signs of treatment benefits were also observed. Therefore,
our results confirm previous good data regarding Ad5/3-D24-GMCSF as a
promising agent for treatment of cancer. Furthermore, our data may prove useful
for clinical development of oncolytic adenoviruses combined with low-dose
chemotherapy for the treatment of advanced sarcoma, melanoma and breast cancer,
and may help to design optimal clinical trials, selecting the right patient
populations. A phase I clinical trial studying Ad5/3-D24-GMCSF has been recently
completed, and phase I/II trials studying combination regimens are in the planning
stages.
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PART B
1. REVIEW OF THE LITERATURE
1.1 Introduction
Cancer is among the most common causes of mortality worldwide, with
approximately 8.2 million cancer-related deaths out of 14.1 million new cases in
2012 (World Cancer Report 2014, WHO, IARC). The five most common cancers
in men are lung, prostate, colorectal, stomach, and liver cancer, while among
women, the most common diagnosed cancers are breast, colorectal, lung, cervix,
and stomach cancer. Cancer is more prevalent in less developed regions, including
Africa, Asia, South and Central America (which account for 70% of the world’s
cancer deaths), which reflects the lack of adequate health care infrastructure and
effective treatment options. Worldwide, it is expected that the annual number of
cancer cases will rise from 14.1 million in 2012 to 22 million within the next two
decades.
Cancer is a heterogeneous disease, related to many different factors, including
genetics, age and potentially avoidable lifestyle risk factors, among which
smoking, lack of physical activity, alcohol use, diet (low fruit and vegetable
intake), overweight and obesity, and viral infections (Worldwide cancer Key Stats
2012). Many cancers can be cured if detected and treated early and adequately. The
most common types of cancer treatment are surgery, chemotherapy, and radiation
therapy. Because cancer is a generic term to indicate a large group of genetic
disorders which can develop in any part of the body, the existence of only one cure
for all cancer types is not expected. Instead, combinations of different therapies can
be used to attack the tumors from different angles.
13
Cancer gene therapy is an emerging field which offers different treatment
approaches aiming at modifying cells using genes. Oncolytic viruses showed great
promise, and several vectors have been tested preclinically and clinically, with
positive clinical phase III results obtained in 2013 (Kaufman et al., 2014), and an
oncolytic adenovirus was approved in China already in 2005 for the treatment of
head and neck cancer (Garber, 2006, Guo and Xin, 2006). In addition to their
ability to replicate and lyse cancer cells, oncolytic viruses can also activate the
immune system, inducing innate and antigen-specific adaptive immunity against
the tumor (Tuve et al., 2009, Alemany, 2008). Viruses can also be armed with
immunostimulatory transgenes, to further improve antitumor properties (Cerullo et
al., 2010). However, despite the promising results with a wide range of tumors,
their overall efficacy needs to be improved, and one method could be to combine
them with current cancer treatment modalities.
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1.2 Sarcoma
Sarcomas are malignant tumors of connective tissues. They comprise a
heterogeneous group of neoplasms of mesenchymal origin and can be generally
grouped into two categories, soft-tissue sarcoma (STS) and primary bone sarcoma
(Table  1), each with different staging and specific treatment modalities (Skubitz
and D'Adamo, 2007). Sarcomas are relatively uncommon in adults (1% of all adult
solid cancers), but they are among the most frequent tumors in young adults and
children, constituting over 20% of all pediatric solid malignant cancers
(Burningham et al., 2012). The three most important prognostic variables are
histologic grade, size, and location of the primary tumor (Ducimetiere et al., 2010).
Primary tumors may remain essentially asymptomatic for extended periods of time.
Therefore, a large proportion of patients develop metastatic disease, which is often
incurable with available treatments, thus survival rate in sarcoma remains low
(McClay, 1989). Although most sarcomas do not have known causes, some risk
factors have been identified: exposure to ionizing radiation, for example radiation
therapy for a previous cancer (Amendola et al., 1989); genetic syndromes, for
example neurofibromatosis type I, Gardner syndrome, Werner syndrome, Li-
Fraumeni syndrome, and familial form of retinoblastoma (Hawkins et al., 1987);
exposure to chemicals (vinyl chloride, dioxin), and human herpesvirus 8 infection,
which plays a role in the development of Kaposi sarcoma (Whitby et al., 1995).
Soft-tissue sarcoma (STS)
Soft tissue sarcomas represent less than 1% of malignancies, and may arise in soft
tissues of the body. The most common types of STS are shown in Table  1.
Localized resected tumors can often be controlled by surgery and radiotherapy,
while for high-grade and metastatic disease, chemotherapy is the primary treatment
modality (Reed and Altiok, 2011). Chemotherapy may be used before or after
15
surgery, to shrink the tumor or prevent its recurrence (Skubitz and D'Adamo,
2007). For the treatment of STS, the two most commonly used chemotherapeutic
agents are doxorubicin and ifosfamide (discussed in section 1.5.2), but also
gemcitabine, dacarbazine, temozolomide and combination of these have been used
(Gottlieb et al., 1972, Awada et al., 2004). The benefits of a single agent vs
combination therapy remain subject of study. More recently, immunotherapeutic
strategies have been developed, which could affect both local and systemic disease,
acting over a prolonged period of time (Finkelstein et al., 2012). Cytokines,
interferon, tumor vaccines, immunologic checkpoint blockade antibodies, adoptive
cell transfer have shown promising results by enhancing immune responses
(D'Angelo et al., 2014). Recently, oncolytic viruses have been used for the
treatment of pediatric sarcomas with encouraging results, and five clinical trials are
currently ongoing (Lettieri et al., 2012).
Table 1. Sarcoma subgroups (Skubitz and D'Adamo, 2007)
Soft-tissue sarcomas Primary bone sarcomas
Malignant fibrous histiocytoma Osteosarcoma
Liposarcoma Ewing sarcoma
Leiomyosarcoma Giant cell tumor
Synovial sarcoma Chondrosarcoma
Dermatofibrosarcoma protuberans
Angiosarcoma
Kaposi sarcoma
Gastrointestinal stromal tumor
Aggressive fibromatosis
Rhabdomyosarcoma
Primary alveolar soft-part sarcoma
16
1.3 Melanoma
Melanoma is a type of skin cancer which develops from melanocytes. The
incidence of melanoma is increasing rapidly, mainly due to increased ultraviolet
radiation (UV) exposure, with around 232 000 new cases diagnosed in 2012
worldwide (2% of all cancers) (Ferlay et al., 2010). Due to its aggressive nature,
malignant melanoma is the most common cause of mortality from skin cancer
worldwide (Ferlay et al., 2010).  The key risk factors for skin cancer are mainly
linked to lifestyle: exposure to solar radiation and carcinogenics, including tobacco
and alcohol, diet, lack of physical activity, overweight and obesity (Cogliano et al.,
2011, Elwood and Jopson, 1997). Based on the stage of the cancer and other
factors, melanoma treatments include surgery (for early-stage melanomas),
chemotherapy, radiation therapy, targeted therapy, immunotherapy or a
combination of immunotherapy and chemotherapy (biochemotherapy) (Bhatia et
al., 2009). The most used chemotherapeutic agents for the treatment of melanoma
are dacarbazine and temozolomide, despite modest efficacy and lack of data for
survival benefit. With advances in the use of immunotherapy, chemotherapy gained
a secondary role and it is generally not used as the initial treatment for patients with
a late-stage disease. Immunotherapy with ipilimumab (anti-cytotoxic T-
lymphocyte-associated antigen 4 antibody) and targeted therapy with BRAF (v-Raf
murine sarcoma viral oncogene homolog B)-inhibitor vemurafenib, have been
shown to improve survival of patients, becoming the preferred approaches for most
patients with metastatic melanoma (Wolchok et al., 2010, Swaika et al., 2014).
With regard to oncolytic viruses, T-VEC (discussed in section 1.8.2) has become
the first oncolytic virus to successfully complete a phase III trial in advanced
melanoma (Andtbacka et al., 2015), and the first oncolytic virus to be approved by
the US Food and Drug Administration (FDA) (Dolgin, 2015).
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1.4 Breast cancer
Breast cancer is the most common cancer in women worldwide, with over 508 000
breast cancer deaths in women in 2011 (Global Health Estimates, WHO 2013).
Breast cancer incidence is particularly increasing in developing countries due to the
lack of early detection programs. The most common risk factors associated with
breast cancer are: familial history, in particular mutations in some genes, including
BRCA1, BRCA2 and TP53; prolonged exposure to endogenous and exogenous
hormones, such as estrogens associated with reproductive factors (early menarche,
late menopause, late age at first childbirth) and use of oral contraceptive and
hormone replacement therapy; alcohol use, overweight and obesity, and inadequate
physical activity (Lacey et al., 2009, Danaei et al., 2005). Breast cancer is
characterized by several distinct biological subtypes associated with specific
biological behavior and different clinical outcomes. Based on the expression of
some particular receptors, tumors can be classified in: estrogen (ER)-receptor and
progesterone (PR)-receptor positive, human epidermal growth factor receptor 2
(HER2)-positive, triple positive (positive for ER, PR and HER2), and triple
negative (not positive for ER, PR and HER2) (Sandhu et al., 2010). Thus, the first
critical step in diagnosis is to determine the stage, the receptor status and the spread
of the tumor, in order to plan the most effective treatment program. Surgery,
radiotherapy and chemotherapy are the most common treatment modalities, but
they can be effective as single therapies only for a small number of cancers, usually
localized and small in size (World Health Organization, 2015). Other common
therapies such as hormone therapy (i.e. aromatase inhibitors or tamoxifen) and
biological treatments (i.e. trastuzumab), are effective only for hormone receptor-
positive and HER2+ breast cancers, often in combination with surgery and
radiotherapy (Buzdar, 2009). With regard to breast cancer treatments using
oncolytic viruses, a herpes simplex oncolytic virus has recently been shown to be
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effective against breast cancer stem cells and for the treatment of metastatic breast
cancer in vitro and in vivo (Wang et al., 2012a, Li et al., 2012).
Triple-negative breast cancer (TNBC)
Triple-negative breast cancer (TNBC) is a subtype of breast cancer defined as ER-,
PR- and HER2- (Sandhu et al., 2010). TNBC (10–15% of breast cancers) is
insensitive to the treatment modalities available for hormone receptor positive and
HER2+ diseases, and thus it is the most aggressive breast cancer subtype,
associated with a poor prognosis (Ovcaricek et al., 2011). TNBC is typically
currently treated with a combination of surgery, radiotherapy and chemotherapy
(Kern et al., 2013, Liedtke et al., 2008, Andre and Zielinski, 2012), but treatment
choices are still limited, highlighting the need for new treatment regimens in this
patient group.
1.5 Conventional and novel cancer therapies
1.5.1 Surgery
Surgery has been the predominant form of treatment for most types of cancer since
1846, when ether was first used as a surgical anesthetic (Gallucci, 2008). For
patients with early-stage cancer, surgery is almost always the first step, and it may
be the only treatment needed. However, following surgery, patients frequently
relapse. Paradoxically, scientific evidence has revealed that surgery itself can
contribute to the development of both local recurrences and distant metastases (van
der Bij et al., 2009), emphasizing the need for other treatment options.
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1.5.2 Radiotherapy
Radiotherapy has been used for treatment of cancer widely since 1895, when X-
rays were discovered, with approximately 40% of cancer patients having it as part
of their treatment (Robinson, 2008). Radiotherapy works by damaging the DNA
directly or indirectly (by creating free radicals within the cells), and thus depriving
cancer cells of their multiplication potential (Baskar et al., 2012). Radiations can be
administered to the tumor from outside the body (external-beam radiation therapy),
from inside (internal radiation therapy, or brachytherapy), or via the systemic
circulation, according to the tumor type, size and location, and to the patient´s
general condition (Robinson, 2008). Radiotherapy can also been used as palliative
treatment (to relieve symptoms and reduce the suffering caused by cancer) or in
combination with other treatment modalities such as surgery (as neoadjuvant or
adjuvant therapy), chemotherapy, or more recently, with immunotherapy
(Robinson, 2008, Warde, 2008, Vatner et al., 2014). Radiotherapy can also affect
normal cells causing side effects, which can occur during the treatment (acute side
effects) or months/years after the treatment (chronic side effects) (Lawrence et al.,
2008). The most common acute side effects include skin irritation, damage to the
salivary glands, hair loss and urinary problems, according to the area which
receives the treatment (Warde, 2008). However, normal cells have more efficient
repair mechanisms than cancer cells, and most acute effects disappear after
treatment ends (Baskar et al., 2012). Other common side effects are nausea, fatigue
and vomiting (Warde, 2008). Chronic side effects can include memory loss,
infertility, fibrosis, and bowel damage (Warde, 2008). Nowadays, researchers are
studying ways to improve the efficacy of radiotherapy while minimizing side
effects. Radioprotectors can be used to protect normal cells from damage caused by
radiation; radiosensitizers can be used to make cancer cells more sensitive to the
effects of radiotherapy (Raviraj et al., 2014). Cisplatin and 5-fluorouracil are two
examples of antitumor drugs which make cancer cells more sensitive to radiation
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(Nagy et al., 2002). Furthermore, preclinical evidence indicated that serotype 5
adenovirus replication per se can also sensitize cancer cells to radiotherapy (Kim et
al., 2009, Rajecki et al., 2009), and a year later Liikanen et al. showed that some
endogenous adenoviral proteins play an important role in radiosensitization in vitro
and in vivo (Liikanen et al., 2010).
1.5.3 Chemotherapy
The era of modern chemotherapy started in early 1940s, when Goodman and
Gilman first administered nitrogen mustard to patients with lymphoma (Goodman
et al., 1984). Chemotherapeutic drugs attack tumors at the cellular level by
interrupting processes necessary for cellular replication (Malhotra and Perry,
2003). The most common chemotherapeutic drugs are “cell cycle phase-
nonspecific”, and thus they have significant activity in multiple phases of the cell
cycle, with a broad spectrum of activity (Malhotra and Perry, 2003). Because of
cytotoxic action on rapidly dividing cells, chemotherapeutic drugs are toxic to
normal cells that are actively multiplying, often depending on the dose used
(Malhotra and Perry, 2003). Low-dosage of certain chemotherapeutic drugs has
been found associated with immunostimulatory properties, instead of increased
cytotoxicity and immunosuppression (Ghiringhelli et al., 2004), providing a good
rationale for combining oncolytic viruses with chemotherapy administered in
metronomic low-dose.
Cyclophosphamide
Cyclophosphamide (CP) belongs to the class of alkylating agents, which interfere
with DNA replication by forming DNA crosslinks (Lind, 2008). As a prodrug, CP
is converted by liver cytochrome P450 enzymes to form the main active metabolite
4-hydroperoxy-cyclophosphamide (4-HP-CP) that has chemotherapeutic activity
21
(Huttunen et al., 2011). CP is commonly used to treat a variety of tumors, as single
agent or in combination with other chemotherapeutic drugs (Shanafelt et al., 2007,
Young et al., 2006, Lien et al., 2013). It has been shown that at higher doses, CP is
associated with increased cytotoxicity and immunosuppression, while at low
continuous dosage it shows immunostimulatory and antiangiogenic properties, as
well as alteration of tumor microenvironment, and eradication of the cancer stem
cell population (Loven et al., 2013). In particular, administration of low-dose CP
(<100 mg/kg) to mice resulted in a significant reduction in regulatory T-cell (T-
reg) frequency and function (Lutsiak et al., 2005). Therefore, the combination of
oncolytic immuno-virotherapy with low-dose CP is an appealing approach.
Doxorubicin
Doxorubicin belongs to the class of anthracyclines, drugs which interact with DNA
by intercalation, inhibiting macromolecular biosynthesis (Lind, 2008). Because
anthracyclines have been recently proposed as inducers of immunogenic cell death
(Casares et al., 2005, Obeid et al., 2007, Galluzzi et al., 2012), their combination
with intrinsically immunogenic agents such as an oncolytic virus armed with
granulocyte-macrophage colony-stimulating factor (GM-CSF), is an appealing
approach. Doxorubicin has been used as first-line chemotherapy for the treatment
of STS, typically in metastatic or unresectable disease, alone or in combination
with ifosfamide (Reed and Altiok, 2011). Results from a large randomized phase
III clinical trial in advanced or metastatic STS (EORTC 62012) show that the
combination of doxorubicin with ifosfamide improves response rates with no clear
benefit in overall survival (Judson et al., 2014).
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Ifosfamide
Ifosfamide is also an alkylating agent, structurally similar to CP, which is
converted by liver cytochrome P450 enzymes to form 4-hydroperoxyifosfamide
(Lind, 2008). It is usually used to treat a wide range of tumors, including STS, as a
single agent or in combination with doxorubicin (Reed and Altiok, 2011). Based on
a large randomized phase III study (EORTC 62012), the combination of ifosfamide
with doxorubicin for the treatment of STS is useful to shrink the tumor before other
interventions or to relieve symptoms, but it does not improve overall survival
(Judson et al., 2014).
1.5.4 Cancer gene therapy
The use of viruses as cancer treatment has been a promising possible therapeutic
approach since the mid-19th century, when cases of tumor regression were observed
in patients during other naturally acquired virus infections (Kelly and Russell,
2007). However, viruses started to be investigated as therapeutic agents in clinical
trials only after development in basic virology in the 1950s. Results from these
early clinical trials were not promising, leading to a period of decreased interest in
virotherapy. In the 1990s, virotherapy gained again interest when viruses started to
be engineered using six main strategies to defeat cancer: 1) viruses can be used as
vectors to replace abnormal or missing genes with healthy ones (for example TP53)
(Pearson et al., 2004); 2) oncolytic viruses are specifically directed to replicate in,
and kill cancer cells via oncolysis; 3) genes coding for immunostimulatory
molecules can be inserted into the viral genome to improve host´s antitumor
immune responses; 4) viruses can be modified by inserting genes which would
render cancer cells more susceptible to chemotherapy, radiotherapy or other
treatments, or 5) by inserting genes that inactivate tumor angiogenesis; 6)
employment of “suicide gene therapy” strategies, where a prodrug is converted in
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the toxic metabolite by a virally-encoded prodrug conversion enzyme, which will
be therefore produced only by virus-infected cancer cells.
The first virotherapeutic agents which received marketing approval for cancer
treatment were a modified replication-deficient adenovirus coding for p53 protein
(Ad-p53) and an oncolytic adenovirus (H101), both developed in China (Pearson et
al., 2004, Garber, 2006). Recent success in clinical trials featuring oncolytic viruses
makes this approach one of the most promising, and subject of this thesis.
1.5.5 Cancer immunotherapy
Immunotherapeutic approaches aim at the activation of patients´ immune system
against cancer. Early immunotherapeutic strategies included infusion of
recombinant cytokines such as interleukin-2 (IL-2), tumor necrosis alpha (TNF-α),
interferon alpha (IFN-α), and granulocyte-macrophage colony-stimulating factor
(GM-CSF),  with promising preclinical and clinical results (Mocellin et al., 2005,
Quesada et al., 1986, Arellano and Lonial, 2008, Atkins et al., 1999). More
recently, the use of monoclonal antibodies, which target a specific antigen, has
become a popular cancer treatment. A randomized phase III clinical trial with the
anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody ipilimumab
resulted in improved survival in patients with metastatic melanoma compared to
conventional therapies (Hodi et al., 2010), and ipilimumab was approved in 2012
for the treatment of metastatic melanoma. Another example of monoclonal
antibody which targets a specific immune checkpoint protein is nivolumab, which
is directed against the programmed cell death-1 (PD-1) receptor on T-cells
(Wolchok et al., 2013). In an early clinical trial, nivolumab showed good
tolerability and durable response rate in patients with metastatic melanoma, renal
and lung cancer (Topalian et al., 2012). Cell-based approaches have also gained
attention in the recent years, when the first cancer vaccine sipuleucel-T was
approved for the treatment of advanced prostate cancer (Kantoff et al., 2010).
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Sipuleucel-T is a mixture of peripheral blood mononuclear cells supplemented with
GM-CSF and a prostate-tumor associated antigen. Several other anticancer
vaccines have been tested, with modest success in clinical trials (Aranda et al.,
2013). Another form of cancer immunotherapy is adoptive T-cell therapy, which
involves the use of autologous tumor-infiltrating lymphocytes (TILs) that have
been genetically-modified and expanded ex vivo and then re-infused to the patient.
The first clinical trial was performed in 1989 (Rosenberg et al., 1990), and since
then, many strategies have been adopted to improve the therapy and circumvent the
obstacles. Among these, the use of T-cell receptor-(TCR) modified T-cells and
chimeric antigen receptor (CAR) T-cells are the most appealing approaches
(Hinrichs and Rosenberg, 2014).
1.6 Adenoviruses
Adenoviruses are DNA viruses that were isolated for the first time in the 1950s in
adenoid tissue-derived cells cultures (Rowe et al., 1953). They are members of the
family Adenoviridae, which is divided into five genera. Human adenoviruses
belong to the Mastadenovirus genus, which is divided into 7 species (A-G), based
on their ability to agglutinate erythrocytes. So far, 59 serotypes of human
adenoviruses have been identified by genotyping techniques (Khare et al., 2011,
Liu et al., 2012).
The primary targets for adenovirus pathology are epithelial cells of the eye,
respiratory and gastrointestinal tracts, leading to keratoconjunctivitis, respiratory
infections and gastroenteritis (Kunz and Ottolini, 2010). They can also infect other
tissue types, including liver and bladder, causing hepatitis (Ozbay Hosnut et al.,
2008) and hemorrhagic cystitis (Manalo et al., 1971). Adenoviral infections are
usually mild, but they can be severe and life-threatening in people with a weakened
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immune system and in infants. Different serotypes have been associated with
different diseases (Kunz and Ottolini, 2010). Human adenoviruses are species-
specific regarding their replication cycle, and thus they are usually non-pathogenic
to animals (Wold and Horwitz, 2007). Exceptions to the species-specificity include
studies suggesting that serotype 5 adenoviruses can replicate in cotton rats, Syrian
hamsters and New Zealand rabbits (Pacini et al., 1984, Thomas et al., 2006,
Gordon et al., 1992).
Serotype 5 adenoviruses, which belong to the species C, have been mainly
associated with self-limiting upper respiratory tract infections. They are the most
used cancer gene therapy vectors, thanks to their well-known structure and
functions, which makes cloning and modifications of the genome relatively easy.
Furthermore, Ad5 is not oncogenic, which is an advantage for safety reasons.
Serotype 3 adenoviruses, which belong to the species B, have been associated with
upper and lower respiratory tract infections, as well as other diseases including
conjunctivitis and pharyngo-conjunctival fever (Kunz and Ottolini, 2010). During
the last 10 years, the use of serotype 3 and 5/3 chimeric adenoviruses (Kanerva et
al., 2002, Kangasniemi et al., 2006, Zheng et al., 2007) for cancer gene therapy has
gained a lot of attention. For example, a serotype 3 oncolytic adenovirus showed
inhibition of tumor growth in vivo, and was well-tolerated in cancer patients with
possible signs of efficacy, with the advantage that this serotype is not neutralized
by neutralizing antibodies directed against adenoviruses of serotype 5 (Hemminki
et al., 2011, Hemminki et al., 2012).
1.6.1 Structure of adenovirus
Adenoviruses are medium-sized (90–100 nm), non-enveloped (without an outer
lipid bilayer) viruses with an icosahedral protein capsid containing a double-
stranded DNA genome (Russell, 2000). The protein capsid is composed of hexon
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proteins with penton proteins at the twelve vertices, and fiber proteins associated
with each penton base of the capsid (Figure  1) (Smith et al., 2010). Fibers are
responsible for adenovirus attachment to the host cell via a receptor on the surface
of the host cell (Campos and Barry, 2007). In addition to these major capsid
proteins, adenoviral capsid also contains minor structural proteins IIIa, VI, VIII and
IX (Smith et al., 2010).
The adenovirus genome is linear, non-segmented double-stranded (ds) DNA that is
circa 36 kilo-base pairs long, and it has a terminal protein associated with each of
the 5' ends of the linear dsDNA, used as primers to initiate viral DNA replication
(Rekosh et al., 1977). Adenoviral genome is associated with core proteins,
important for creating links between genome and capsid, and for packaging of the
virions (Campos and Barry, 2007). The genome consists of immediate early (E1A),
early (E1B, E2, E3, E4), intermediate (IVa2, IX) and late genes (L1-L5) (Russell,
2000)
Figure 1. Adenovirus particle structure and major capsid proteins.
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1.6.2 Adenovirus life cycle
Adenoviruses are obligate intracellular parasites, fully dependent on the host-cell´s
replication machinery. The first step of the adenovirus life cycle is the entry into
the host cell, which is initiated by the binding of virus knob proteins to the cell
primary receptors (Campos and Barry, 2007). This is followed by secondary
interactions between a penton base motif and cellular integrin molecules (Mathias
et al., 1998), which mediate internalization of the virus particle via clathrin-coated
vesicles, and following endocytosis (Wang et al., 1998). Once the virus is in the
endosome, a process of acidification leads to digestion of pentons and capsid
components, with subsequent release of the virus into the cytoplasm (Campos and
Barry, 2007). The virus, surrounded by only hexon proteins, is then transported
with the help of cellular microtubules to the nuclear pore complex, where the
remaining capsid proteins are dissociated, and the viral genome is released into
the nucleus (Greber et al., 1997). In the nucleus, viral gene expression is initiated,
and new viral particles can be generated (Russell, 2009). The immediate early gene
E1A is the first viral gene that is expressed and it activates the transcription of
other early genes (Volpers and Kochanek, 2004). Through binding to
retinoblastoma protein (Rb) and subsequent release of E2F factor, E1A activates
adenoviral E2 gene expression and transcription of the other early genes (E1B, E2,
E3, E4) (Russell, 2000). E1-E4 early genes are expressed before viral DNA
replication (early phase) and they are responsible for expressing mainly regulatory
proteins. They are involved in the activation of other viral genes and in the
inhibition of anti-adenoviral immune responses and apoptosis to prolong host-cell
survival (Berk, 2005). After transcription of the early genes, replication of viral
DNA can occur. The primer for the replication is a terminal protein covalently
bound to each of the 5' ends of the genome (Rekosh et al., 1977). Intermediate
genes IVa2 and IX are expressed next (late phase) and they activate the major late
promoter, with subsequent transcription of late genes L1-L5 for structural
28
proteins production (Russell, 2009). Once viral DNA has been replicated and
sufficient quantities of structural proteins have been produced, the new virions are
assembled and released from the cell, as a result of virally-induced cell lysis.
The primary high-affinity receptor identified for species C adenoviruses (which
includes Ad5) is Coxsackie-adenovirus receptor (CAR) (Bergelson et al., 1997).
CAR-receptor was subsequently identified to be the primary receptor for also other
adenoviral species, including A, D, E and F (Roelvink et al., 1998). CAR belongs
to the immunoglobulin superfamily, and it is involved in the formation of tight
junctions between epithelial cells (Cohen et al., 2001). Thus, it is still unclear how
the virus can reach the receptor, given its basolateral location. It has been proposed
that binding between adenovirus fiber proteins and CAR facilitates the spread of
the virus in the epithelium by disrupting the tight junctions (Walters et al., 2002).
Secondary interactions involve an Arg-Gly-Asp (RGD) motif in the adenoviral
penton base, which binds to αβ integrins on the cell surface (Mathias et al., 1998).
In addition to CAR and integrins, also fiber shaft interactions with heparan sulfate
proteoglycans on the cell surface are important for virus entry (Dechecchi et al.,
2001).
Group B human adenoviruses (which include Ad3) do not use CAR as the primary
receptor. The primary receptor for some species B serotypes was identified as
CD46 (Gaggar et al., 2003), but for other species B serotypes, like serotype 3,
another high-affinity receptor was recently identified as desmoglein-2 (DSG-2)
(Wang et al., 2011). In addition, other receptors and molecules might play a key
role in virus entry. For serotype 3 adenoviruses, CD80 and CD86 have been
identified as additional receptors (Short et al., 2004), while for species C
adenoviruses there are some reports suggesting that major histocompatibility
complex (MHC) molecules (Hong et al., 1997), scavenger receptor A (Haisma et
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al., 2009), and vascular cell adhesion molecule-1 (Chu et al., 2001) could function
in this capacity as well.
1.6.3 Immune responses to adenoviral infection
When a virus infects host organisms, it is immediately recognized as “non-self
invading pathogen”, leading to the development of an antiviral immune response.
The innate immune system is the first-line defense against pathogens. As soon as
the adenoviral fiber proteins bind to the receptor on cell surface, the viral capsid is
recognized as foreign, triggering a rapid induction of inflammatory cytokines
(Tamanini et al., 2006). Thereafter, adenoviral DNA is sensed by receptors on
dendritic cells (DCs), such as Toll-like receptor 9 (TLR-9), leading to activation of
immune cells (macrophages and natural killer cells) (Huang and Yang, 2009,
Cerullo et al., 2007) and secretion of large amounts of pro-inflammatory cytokines
(IL-6, IL-8, IL-12, TNFα) and type I interferons (Wold and Horwitz, 2007, Huang
and Yang, 2009). Cytokine and interferon responses recruit natural killer (NK)-
cells, granulocytes, macrophages and DCs locally (Hendrickx et al., 2014). Later,
an adaptive antiviral immune response is activated by recruitment of specific B and
T lymphocytes, which is initiated by DCs (Jooss and Chirmule, 2003). DCs, after
recognizing adenoviral DNA by TLR-9, process the internalized adenoviral
fragments and present the viral antigens to CD4+ helper and CD8+ cytotoxic T
cells (CTL), via MHC, providing also costimulatory signals (Muruve, 2004). This
occurs in local lymph nodes. Activated CTL directly kill virus-infected cells which
express viral antigens on MHC-I class molecules on their surface. Activated CD4+
helper T cells are involved in B lymphocyte activation, leading to antibody
production against adenoviral proteins, in particular hexon and fiber proteins
(Bradley et al., 2012). Furthermore, adaptive immunity creates an immunological
memory which will protect the host from potential virus reinfections. If a second
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infection reoccurs later, the immune system will more rapidly recognize viral
antigens and activate antiviral immune responses (Nayak and Herzog, 2010).
1.7 Modified adenovirus vectors for treatment of cancer
Adenoviral vectors have been used extensively in gene therapy to treat diseases by
transferring functional or therapeutic genes into cells. Adenoviral genome can be
easily modified to target adenovirus to certain cell types, including cancer cells
(Beatty and Curiel, 2012). Viral selectivity to cancer cells can be achieved by
modifying the viral capsid (transductional targeting) or by controlling the
expression of genes essential for virus replication, by gene-deletion or insertion of
specific promoters (transcriptional targeting) (Barnett et al., 2002). The use of
adenoviral vectors for gene therapy has many advantages: adenoviruses can infect
both replication and non-replicating cells, adenoviral DNA does not integrate into
the host genome, large transgene can be inserted into the adenoviral genome,
reaching high levels of transgene expression (Russell, 2000).
1.7.1 Transductional targeting
Transductional targeting refers to alterations of the interactions by which the virus
enters into the host cells. This can be achieved by modifications on the viral capsid
proteins. Along with the findings that CAR, the primary receptor of serotype 5
adenoviruses, is expressed at low and variable levels on cancer cells and that it is
often downregulated in tumors (Kanerva and Hemminki, 2004), much effort has
been put in redirect the virus to other receptors, expressed at higher levels on tumor
cells. One method, in order to achieve increased transduction of tumor cells, is the
generation of chimeric adenovirus constructs, through replacement of the entire
adenovirus knob with a knob from a different serotype. With the discovery that the
serotype 3 primary receptor, later identified as DSG-2 (Wang et al., 2011) is highly
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expressed on cancer cells (Tuve et al., 2006, Kanerva et al., 2002), Ad5/3 chimeras
were generated through placement of Ad3 fiber knob into the Ad5 backbone
(Krasnykh et al., 2001), with promising preclinical and clinical efficacy and safety
data (Kanerva et al., 2003, Kangasniemi et al., 2006, Volk et al., 2003, Ranki et al.,
2007, Guse et al., 2007, Zheng et al., 2007, Koski et al., 2010).
Another common modification to improve cancer cell transduction is the insertion
on the virus capsid of ligands that bind adhesion molecules overexpressed on
cancer cell surface (Nicklin et al., 2005, Hall et al., 2010). For example, polylysine
residues and RGD-motif can be added to the virus fiber C-terminus or HI-loop,
redirecting the virus attachment to heparan sulfate proteoglycans and cell surface
integrins (Wickham et al., 1996, Dmitriev et al., 1998). Penton base and hexon
modifications have also been investigated (Vigne et al., 1999, Wickham et al.,
1995), as well as insertion of polylysine to the minor capsid protein IX (Dmitriev et
al., 2002).
1.7.2 Transcriptional targeting
Transcriptional targeting refers to modifications of viral genes essential to viral
replication, in order to control their transcription. Genetic deletions and insertion of
tumor-specific promoters are the main approaches for transcriptional targeting
(Berk, 2005, Robson and Hirst, 2003). Depending on the type of deletion, viruses
can be divided in replication-deficient and conditionally replicating vectors (Lai et
al., 2002, Dobbelstein, 2004).
Replication-deficient adenoviral vectors
Replication-deficient adenoviruses are generated by large deletions of their genes,
so that they are unable to replicate in cells (Lai et al., 2002). These vectors are
mainly used to deliver transgenes, for cancer therapy as well as other genetic
32
disorders. The first generation vectors were deleted of the E1 gene region and often
also E3 regions, with a transgene inserted in place of the deleted E1 gene (Hall et
al., 2010). Usually, these viruses can accommodate transgene sequences not larger
than 8.2 kilo-base pairs (Alba et al., 2005), to avoid genomic instability (Bett et al.,
1993). These vectors are unable to replicate in cells due to the lack of E1 gene, but
they can infect cells normally and deliver therapeutic transgenes, such as tumor-
suppressor proteins (Nielsen et al., 1998), anti-angiogenic molecules (Im et al.,
2001), prodrug-converting enzymes (Tyynelä et al., 2002), monoclonal antibodies
(Jiang et al., 2006), and cytokines (Sung et al., 2002). However the transgene
expression is transient due to lack of virus replication and activation of host
immune responses, which eradicate the vector (Muruve, 2004, Alba et al., 2005).
Second generation vectors were designed to overcome the limitations of the first-
generation adenoviruses. These new-generation vectors have additional viral gene
deletions in the E2 and E4 regions, to increase the cloning capacity of the vector
and to decrease antiviral immune responses (Danthinne and Imperiale, 2000, Hall
et al., 2010). However, these vectors still had the same problems of rapid immune
eradication and transient gene expression, leading to the development of a third-
generation of vectors, called “gutless” or “high capacity” vectors (Alba et al.,
2005). These vectors lack of all coding viral genes except the 5´and 3´ inverted
terminal repeats and the packaging signal. They can accommodate large transgenes
up to 36 kilo-base pairs, but for virus production they require co-infection with a
helper adenovirus that provides the missing essential genes. For this reason, they
are often called helper-dependent adenoviruses (Alba et al., 2005). The advantages
of these vectors include a minimal immune response against the virus and a longer
transgene expression (Seiler et al., 2007). Thus, these vectors have been tested for
gene replacement therapies where long-time transgene expression is needed (Ginn
et al., 2013).
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 Conditionally replicating adenoviral vectors
Conditionally replicating adenoviral vectors (CRAds), or oncolytic adenoviruses,
are viruses that selectively replicate in cancer cells (Jounaidi et al., 2007). These
vectors are generated by modifications of the viral genome to prevent their
replication in normal cells. These modifications include small deletions in essential
genes which render the virus replication-deficient in normal cells but not in cancer
cells that possess genetic deficiencies that complement the viral defects (Jounaidi et
al., 2007). The first and the most known oncolytic adenovirus is ONYX-015. This
virus has deletions in the E1B-55k gene, which is involved in inhibition of p53
protein (Martin and Berk, 1998). Thus, ONYX-015 was expected to replicate only
in cells with deficiencies in the gene coding for p53 protein and not in cells with
the intact gene (Bischoff et al., 1996). However, given the many functions of E1B-
55k protein, deletions in E1B-55k gene also reduced cell killing potency (Dix et al.,
2001), and it was later reported that the mechanism of selectivity is related to
defects in viral mRNA export, rather than the lack of virus replication (O'Shea et
al., 2004). Another strategy to direct virus replication to cancer cells is a partial
genomic deletion. An example is a 24-base pair deletion in the constant region 2 of
the E1A gene (Fueyo et al., 2000). The rationale behind this strategy is that E1A
protein normally binds to the Rb protein, releasing the E2F transcription factor.
When released, E2F activates genes that promote cell-cycle S phase, allowing virus
replication (Whyte et al., 1988). The protein produced from the modified E1A
gene, lacking the 24-base pair sequence, is unable to bind to Rb, and thus E2F
remains bound to Rb, blocking viral DNA replication. In cancer cells, Rb/p16
pathway is often defective (Sherr and McCormick, 2002), and thus free E2F is
constantly available in these cells, allowing adenoviral replication even without
E1A. Oncolytic adenoviruses carrying a 24-base pair deletion in E1A gene have
been successfully tested preclinically and clinically (Kanerva et al., 2003,
Hakkarainen et al., 2009).
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Oncolytic viruses can be also generated by the insertion of tumor-specific
promoters that control viral replication. Expression of E1A gene can be controlled
by the insertion of a promoter that is active in particular tumor cells. For example,
E1A gene controlled by prostate-specific antigen (PSA) promoter resulted in
selective virus replication in prostate tumors expressing PSA (Rodriguez et al.,
1997). Other examples of tumor-specific promoters that have been used are
carcinoembryonic antigen (CEA) for colorectal cancer (Li et al., 2003), α-
fetoprotein for liver cancer (Kim et al., 2002) and tyrosinase for melanoma (Zhang
et al., 2002). In addition to these tumor-specific promoters, which have limited
applicability due to their tumor-type specificity, promoters active in a variety of
cancer types, such as cyclo-oxygenase 2 (Cox-2) promoter (Kanerva et al., 2004,
Bauerschmitz et al., 2006, Pesonen et al., 2010), vascular endothelial growth factor
(VEGF) promoter (Kanerva et al., 2008), E2F promoter (Rojas et al., 2009,
Hemminki et al., 2015) and human telomerase reverse transcriptase (hTERT) (Ito
et al., 2006, Hemminki et al., 2012, Diaconu et al., 2012, Pesonen et al., 2012b)
have also been employed.
1.8 Arming adenoviruses with immunostimulatory transgenes
The primary efficacy of oncolytic viruses was previously thought to be related to
their selective replication and lytic effect on cancer cells. Later, preclinical and
clinical evidence suggested that adenovirus replication activates immune responses
against virus-infected cancer cells, mediating antitumor efficacy (Tuve et al.,
2009). However, because virus-induced immune reactions are not sufficient to
eradicate tumors (Tuve et al., 2009) researchers started to generate viruses armed
with immunostimulatory molecules, to increase antitumor potency and to boost the
immune system against tumor cells (Cerullo et al., 2010). Cytokines have a key
role in immune reactions, and recombinant cytokines such as IL-2, GM-CSF,
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TNFα and IFNα have been tested clinically for the treatment of certain tumor types
(Lee and Margolin, 2011, Lejeune et al., 1998). However, the main problems with
infusion of cytokines were related to adverse reactions and systemic toxicity, while
the concentration at the tumor site often remained low (Li et al., 2005). Thus, an
armed adenovirus would direct local cytokine-production by infected cancer cells,
ensuring local concentration at the tumor site while minimizing systemic adverse
reactions. A multitude of oncolytic and replication-deficient viruses have been
armed with various immunostimulatory molecules, including TNFα, IL-2, GM-
CSF, IL-12, IL-15, CD40-ligand, IFNα, IFNβ and IFNγ (Li et al., 2005).
1.8.1 GM-CSF
GM-CSF is one of the most potent cytokines that stimulates cells of the innate
immune system including NK cells, DCs, and macrophages, potentially resulting in
antitumor immunity (Dranoff, 2003). Increased levels of local GM-CSF also
induce recruitment of monocytes and their maturation into macrophages and DCs
(Chang et al., 2004). However, similarly to other cytokines, systemic use of GM-
CSF is compromised by toxic side effects and induction of potentially harmful
myeloid-derived suppressor cells, while its efficacy may remain limited due to the
low local concentration in tumors (Serafini et al., 2004, Arellano and Lonial, 2008).
Therefore, local production of GM-CSF by cancer cells, could ensure both
sufficient concentration at the tumor site and minimal systemic exposure (Koski et
al., 2010). Oncolytic adenoviruses coding for GM-CSF have previously shown
promising antitumor efficacy and signs of immune response activation against the
tumors in preclinical models (Ramesh et al., 2006, Lei et al., 2009, Koski et al.,
2010). Furthermore, good tolerability and promising signs of antitumor efficacy
have been observed in cancer patients, both in early clinical data (Koski et al.,
2010, Cerullo et al., 2010) and in phase I clinical trials (Chang et al., 2009, Oncos
Therapeutics Ltd.).
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1.8.2 Oncolytic viruses armed with GM-CSF
A multitude of vectors (viral and non-viral, replication-deficient and oncolytic)
have been armed with GM-CSF. With regard to conditionally replicating viruses,
promising GM-CSF-coding oncolytic viruses include adenovirus, vaccinia and
herpes simplex viruses.
CG0070 is a serotype 5 oncolytic adenovirus armed with GM-CSF, with the E2F
promoter to control E1A expression (Burke, 2010). In 2006, in vitro and in vivo
studies showed selective replication, cytotoxicity, production of GM-CSF, and
antitumor efficacy of CG0070 in several human bladder transitional cell carcinoma
(TCC) models, suggesting a potential utility of this oncolytic agent for the
treatment of bladder cancer (Ramesh et al., 2006). Indeed, preliminary results of a
phase I trial in 35 patients treated with single or multiple intravesical infusions of
CG0070 at multiple-dose levels, showed tolerable safety profile and antibladder
cancer activity, with GM-CSF expression and virus replication (Burke et al., 2012).
An Integrated Phase II/III, open label, randomized and controlled study of the
safety and efficacy of CG0070 in patients with non-muscle invasive bladder cancer
is currently ongoing (ClinicalTrials.gov).
KH901 is a serotype 5 adenovirus coding for GM-CSF and with a modified hTERT
promoter to control the E1A gene (Chang et al., 2009). In 2009, a phase I study of
this oncolytic adenovirus in 23 patients with recurrent head and neck cancer (HNC)
showed feasibility of intratumoral administration of the virus, biological activity
(with virus replication and high GM-CSF levels in serum and two disintegrated
tumors), and good tolerability. Despite the good data, no objective treatment
responses were recorded, thus evaluation of efficacy would require a phase II trial
(Chang et al., 2009).
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JX-594 is an oncolytic vaccinia virus, with GM-CSF in the thymidine kinase (TK)
gene. The first phase I clinical trial in 1999 showed promising results in 7
melanoma patients treated with intratumoral injections of the virus, with signs of
safety, antitumor and immunological efficacy (Mastrangelo et al., 1999). Another
phase I clinical trial was performed in 2008 in 14 patients with primary or
metastatic hepatic cancer with intratumoral injections of the virus: the results were
still promising, with disease control achieved in 9 out of 10 evaluable patients
(Park et al., 2008). In 2011, ten patients with metastatic melanoma were treated
with a low viral dose, equivalent to only 10% of the maximum tolerated dose in the
previous trial (1x109 plaque forming units). Circulating virus was detected,
suggesting virus replication and shedding into the blood. Furthermore infiltration of
lymphocytes into the tumors and necrosis of tumor tissues were observed (Hwang
et al., 2011). In 2013, a randomized phase II dose-finding trial in 30 patients with
liver cancer showed good tolerability, oncolytic and immunotherapy mechanisms
of action, tumor responses in injected and non-injected lesions, and dose-related
survival (Heo et al., 2013).
Talimogene laherparepvec (T-VEC) is a conditionally replicating herpes virus
coding for GM-CSF, which was first studied in a phase I clinical trial in 2006 (Hu
et al., 2006). Preliminary results showed good tolerability, signs of virus replication
and antitumor efficacy, tumor necrosis and GM-CSF expression in 30 patients with
melanoma, HNC, breast and gastrointestinal cancer treated with intratumoral
injections (Hu et al., 2006). In 2009 and 2010, T-VEC was further studied as a
single agent in late stage melanoma (Senzer et al., 2009), or in combination with
chemoradiotherapy in head and neck squamous cell cancer (Harrington et al.,
2010). Based on promising results, a phase III trial study was recently completed
on 436 patients with advanced melanoma, and T-VEC demonstrated a significant
improvement in the durable response rate (DRR) vs subcutaneous GM-CSF, with a
tolerable safety profile (Kaufman et al., 2014). T-VEC has recently become the
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first oncolytic virus approved by the US Food and Drug Administration (FDA)
(Dolgin, 2015).
Ad5-D24-GMCSF and Ad5-RGD-D24-GMCSF are serotype 5 oncolytic
adenoviruses with GM-CSF inserted in the E3 region, and the 24-base pair deletion
in E1A for tumor-selectivity (Cerullo et al., 2010, Pesonen et al., 2012a). Ad5-
RGD-D24-GMCSF also contains a RGD-4C modification of the fiber to improve
virus transduction in cancer cells which frequently express high levels of αβ
integrins on their surface. These viruses have been used in the ATAP program
(discussed in section 3.6.1) to treat 20 and 7 patients, respectively, with advanced
solid tumors. Results were promising, although ATAP is not a clinical trial,
showing good tolerability, virus replication, GM-CSF production restricted to the
tumor and low systemic GM-CSF levels. Furthermore both antiviral and antitumor
T cell responses were detected (Cerullo et al., 2010, Pesonen et al., 2012a).
Ad5/3-E2F-D24-GMCSF is a quadruple modified oncolytic adenovirus expressing
GM-CSF (Hemminki et al., 2015). It contains a tumor specific E2F1 promoter
driving the viral E1A gene, which is deleted at the Rb-protein binding site. The
fiber features a knob from serotype 3 to improve virus transduction to tumor cells.
The virus showed promising results in vitro and in vivo, and thus 13 advanced
cancer patients were treated in the ATAP, with good tolerability and evidence
suggesting induction of antitumor immune responses, signs of antitumor efficacy,
and accumulation of immunological cells, especially T-cells, to tumors after
treatment (Hemminki et al., 2015).
Ad5/3-D24-GMCSF
Ad5/3-D24-GMCSF is a 5/3 capsid chimeric and p16/Rb pathway-selective
oncolytic adenovirus armed with human GM-CSF (Koski et al., 2010). This virus is
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expected to have a threefold mechanism of action: 1) transduction of and
replication in cancer cells, with subsequent tumor cell lysis and release of tumor-
associated antigens (TAAs) and danger signals at the tumor site; 2) local
production of GM-CSF, which recruits and activates DCs, with subsequent
presentation of TAAs to CD4+ and CD8+ T-cells in the local lymph node, thus
activating an antitumor immune response; 3) local GM-CSF recruits NK cells to
the tumor site, which directly kill tumor cells (Dranoff, 2003). In preclinical
testing, Ad5/3-D24-GMCSF showed good oncolytic potential and production of
functionally active human GM-CSF in vitro (Koski et al., 2010). Furthermore, the
virus was effective in inhibiting tumor growth of syngeneic pancreatic tumors in
immunocompetent Syrian hamsters, and it was more effective when combined with
low-dose CP (Koski et al., 2010), due to CP effect on regulatory T-cells
(Ghiringhelli et al., 2007, Cerullo et al., 2011). Selectivity of replication and local
replication-linked production of GM-CSF in tumors were also demonstrated (Koski
et al., 2010). Following preclinical testing, early clinical data from 21 advanced
cancer patients treated in the ATAP showed good tolerability, with promising signs
of antitumor immunity (Koski et al., 2010). In cancer patients, Ad5/3-D24-GMCSF
also showed increased tumor cell autophagy, induction of antitumor immune
responses and promising safety and efficacy when combined with temozolomide
and low-dose CP (Liikanen et al., 2013). Although Ad5/3-D24-GMCSF was
detected in patient serum for long periods even after a single dose, multiple
injections of the virus showed improved tumor transduction and enhanced
antitumor immunity, without increasing adverse reactions (Kanerva et al., 2013). A
phase I clinical trial featuring Ad5/3-D24-GMCSF has also been completed in
2013, but the data has not yet been published, and phase I/II trials in several solid
tumors are in planning (Oncos Therapeutics Ltd.).
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2. AIMS OF THE STUDY
The aim of this thesis is to study the utility of Ad5/3-D24-GMCSF in the treatment
of sarcoma, melanoma and breast cancer, as a single agent or in combination with
chemotherapeutics, and to observe feasibility and safety in patients.
Specific aims
· To assess the efficacy of Ad5/3-D24-GMCSF for treatment of sarcoma,
melanoma and breast cancer in preclinical models.
· To study the effects of virally-expressed GM-CSF on cells of the immune
system.
· To analyze the safety, efficacy and survival of cancer patients treated in an
Advanced Therapy Access Program (ATAP).
· To improve antitumor efficacy by combining Ad5/3-D24-GMCSF with
chemotherapeutics that possess immunogenic properties (doxorubicin and
ifosfamide) and that selectively reduce circulating regulatory T-cells
(cyclophosphamide).
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3. MATERIALS AND METHODS
Materials and methods are described in more detail in the original publications.
3.1 Cell lines
Characteristics of the cell lines used in the studies are described in Table 2.
Table 2. Description of the cell lines used in the studies
Cell line Description Source Study
A549 Human lung adenocarcinoma
cells
ATCC1 I-IV
293 Transformed human
embryonic kidney cells
ATCC1 I-IV
SK-LMS-1 Human leiomyosarcoma cells ATCC1 I, II
HT-1080 Human fibrosarcoma cells ATCC1 I, II
RD Human rhabdomyosarcoma
cells
ATCC1 I, II
SW872 Human liposarcoma cells ATCC1 I, II
SW982 Human synovial sarcoma
cells
ATCC1 II
DDT1-MF2 Syrian hamster
leiomyosarcoma cells
provided by Prof. Wold2 I, II
SK-MEL-28 Human melanoma cells ATCC1 III
C8161 Human melanoma cells provided by Prof. Welch3 III
A375M Human melanoma cells provided by Prof. Fidler4 III
Mel888 Human melanoma cells provided by Dr. Schlom5 III
Mel624 Human melanoma cells provided by Dr. Schlom5 III
pMelL Human low-passage
melanoma cells
provided by Dr. Nettelbeck6 III
RPMI 1846 Syrian hamster melanoma
cells
ATCC1 III
B16-OVA Mouse melanoma cells provided by Prof. Vile7 II
MDA-MB-436 Human triple-negative breast
cancer cells
ATCC1 IV
1 American Type Culture Collection (Manassas, VA, USA)
2 Prof. William S.M. Wold (St. Louis University, School of Medicine, MO, USA)
3 Prof. Danny R. Welch (University of Alabama, Birmingham, AL, USA)
4 Prof. Isaiah J. Fidler (University of Texas MD Anderson Cancer Center, Houston, TX, USA)
5 Dr. Jeffrey Schlom, (National Cancer Institute, Bethesda, MD, USA)
6 Dr. Dirk M. Nettelbeck (German Cancer Research Center, DKFZ, Heidelberg, Germany)
7 Prof. Richard Vile (Mayo Clinic, Rochester, MN, USA)
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Human lung adenocarcinoma cells A549 and transformed human embryonic
kidney cells 293 were used for virus production. All cell lines were cultured under
the recommended conditions.
3.2 Adenoviruses
Viruses were propagated on A549 (oncolytic viruses) or 293 (replication-deficient
viruses) cells and purified on cesium chloride gradients. Virus particle
concentration was determined by measuring the absorbance at 260 nm, and the
number of infectious particles per ml (pfu/ml) was assessed by tissue culture
infectious dose 50 assay (TCID50) on 293 cells. Virus constructs were checked by
polymerase chain reaction (PCR) for the presence of transgenes and genetic
modifications, as well as for the absence of wild-type virus contamination. Details
on virus cloning are described in the original publications or references.
3.2.1 Replication-deficient vectors
Replication-deficient vectors used in the studies are listed and described in Table
3. All replication-deficient constructs are deleted for E1A gene, and luciferase
transgene is inserted in the deleted E1A region under cytomegalovirus (CMV)
promoter. The Ad5/3 chimera was generated through replacement of the Ad5 fiber
knob with the Ad3 knob, to increase transductional targeting. This is associated
with high expression of serotype 3 adenovirus-receptor desmoglein-2 (DSG-2) in
cancer cells (Wang et al., 2011). RGD-4C modification in the fiber HI loop
enhances binding to cellular integrins and to cell-surface molecules containing
heparan sulfate.
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Table 3. Description of the replication-deficient viruses used in the studies
Virus name Description Source/reference(s) Study
Ad5luc1 Serotype 5 wild type with
luciferase in E1A
(Kanerva et al., 2002);
(Krasnykh et al., 2001)
I, III, IV
Ad5/3luc1 Chimeric 5/3 fiber with
luciferase in E1A
(Kanerva et al., 2002) I, III, IV
Ad5lucRGD Serotype 5 wild type, RGD-
4C motif in HI loop,
luciferase in E1A
(Dmitriev et al., 1998) I, III, IV
Ad3CMV-luciferase Serotype 3 with luciferase
in  E1A  under  CMV
promoter
(Fleischli et al., 2007) I, III, IV
3.2.2 Conditionally replicating vectors
Conditionally replicating viruses used in the studies are described in Table 4.
Ad5wt is an unmodified wild-type serotype 5 adenovirus Ad300wt, purchased from
ATCC. All the other oncolytic adenoviruses have a 24-base pair deletion in the Rb-
binding site in the constant region CR2 of the E1A gene. As a result, these viruses
replicate only in cells with Rb/p16 pathway defects, including most human tumor
types (Fueyo et al., 2000). Ad5/3-D24-GMCSF (Koski et al., 2010) has the human
granulocyte-macrophage colony-stimulating factor (GM-CSF) in the E3 gene, to
stimulate antitumor immunity (Cerullo et al., 2010).
Table 4. Description of the oncolytic viruses used in the studies
Virus name Description Reference(s) Study
Ad5wt Serotype 5 wild type
adenovirus Ad300wt
ATCC I, III, IV
Ad5/3-D24 Chimeric 5/3 fiber, 24-base
pair deletion in E1A
(Kanerva et al., 2003) I-IV
Ad5/3-D24-GMCSF Chimeric 5/3 fiber, 24-base
pair deletion in E1A,
human GM-CSF in E3
(Koski et al., 2010) I-IV
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3.3 Chemotherapeutic agents
Chemotherapeutics used in the studies are described in Table  5. Doxorubicin
(Medac GmbH, Wedel, Germany) was diluted in 0.9% sodium chloride (NaCl)
solution (B. Braun, Melsungen, Germany). Ifosfamide (Holoxan®, Baxter,
Deerfield, IL) and 4-hydroperoxyifosfamide powder (Niomech GmbH, Bielefeld,
Germany) were reconstituted in sterile water. Cyclophosphamide (Sendoxan,
Baxter) was diluted in 0.9% NaCl solution. 4-hydroperoxycyclophosphamide
(Niomech GmbH, Bielefeld, Germany) was diluted in sterile water.
Table 5. Description of the chemotherapeutic agents used in the studies
Name Description Source Study
Doxorubicin Anthracycline, interacts
with DNA by
intercalation
Medac GmbH,
Wedel,
Germany
II
Ifosfamide Alkylating agent,
interferes with DNA
replication by forming
DNA crosslinks
Holoxan®,
Baxter,
Deerfield, IL
II
4-hydroperoxyifosfamide Pre-activated form of
ifosfamide
Niomech
GmbH,
Bielefeld,
Germany
II
Cyclophosphamide Alkylating agent,
interferes with DNA
replication by forming
DNA crosslinks
Sendoxan,
Baxter
III, IV
4-hydroperoxycyclophosphamide First active metabolite
of cyclophosphamide
Niomech
GmbH,
Bielefeld,
Germany
IV
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3.4 In vitro studies
3.4.1 Transduction assays (I, III)
Cells were seeded on 24-well plates and infected in triplicates with Ad5luc1,
Ad5/3luc1, Ad5lucRGD or Ad3CMV-luciferase at doses of 1, 10, 100 and 1000
viral  particles  (VP)/cell  for  2h  at  37°C  in  200  µl  of  growth  medium  (GM)
containing 2% of fetal bovine serum (FBS). Cells were then washed and 10% GM
added. After 24h, cells were lysed by incubation with Luciferase Cell Culture Lysis
Reagent for 20 minutes at room temperature. Cell lysates were analyzed for
luciferase expression using Luciferase Assay System (Promega, Madison, WI,
USA) and TopCount plate reader luminometer.
3.4.2 Cytotoxicity and combination assays (I-IV)
Cells were seeded at 5000-10 000 cells/well in GM containing 2-5% FBS. After
overnight incubation, cells were infected in triplicates with tenfold dilutions of
viruses, from 1000 VP/cell to 1 VP/cell. 24h post-infection, 100 µl of fresh 10%
GM was added to each well, and cells were incubated at 37°C until cytotoxicity
was measured. Cell viability was measured using CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega) when a cytopathic effect (CPE) was
observed in cells infected with the highest dilution of one of the viruses. In study II,
cells were infected with 1000 VP/cell of virus alone or in combination with 5 ng/ml
of doxorubicin and 150 ng/ml of 4-hydroperoxyifosfamide. Cells were incubated at
37°C, and cell viability was measured after 14 days. In study III, cells were
infected in quadruplicates with tenfold dilutions from 100 VP/cell to 0.01 VP/cell,
and 100 µl of 10% GM was added after 18h. In study IV, cells were infected with
tenfold dilutions, from 1000 VP/cell to 1 VP/cell of virus alone or in combination
with cyclophosphamide (0.0075, 0.05 mg/ml) or 4-hydroperoxycyclophosphamide
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(0.001, 0.0025, 0.005 mg/ml). Cell viability was measured 5 days post-infection.
Cell viability is expressed relative to uninfected control cells, whose mean
absorbance is set as 100% viability.
3.4.3 Virus replication in Syrian hamster and human sarcoma cells (I, II)
In study I, we checked if Ad5/3-D24-GMCSF virus replicated in hamster
leiomyosarcoma DDT1-MF2 cells. Cells were plated at 10 000 cells/well on two
96-well plates and infected with Ad5/3-D24-GMCSF in 10 replicates at 0.0001–
1000 VP/cell in 100 mL of 2% GM. CPE was followed for 12 days, and the
amount of infectious particles was calculated daily, based on the standard TCID50
assay. In study II, adenoviral replication was assessed in Syrian hamsters DDT1-
MF2 cells and in human sarcoma cells. Cell culture monolayers were harvested at
selected time points and total DNA was extracted with QIAamp DNA Mini Kit
(Qiagen, Valencia, CA). In hamster DDT1-MF2 cells, adenoviral E4 copy number
was measured with quantitative PCR (qPCR), 72 h after infection of cells with
1000 VP/cell of Ad5/3-D24-GMCSF with or without chemotherapy (doxorubicin
and 4-hydroperoxyifosfamide), and normalized to hamster housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). In human sarcoma cells
adenoviral E4 copy number was measured with qPCR, 24, 48, 72 and 96 h after
infection with 10 VP/cell of Ad5/3-D24-GMCSF alone or in combination with
doxorubicin (50 ng/ml), and normalized to human beta-actin gene. Details on the
primers and probes are in the original publication or references.
3.4.4 Effects of virally-expressed GM-CSF on human monocytes (III)
To study the effects of GM-CSF encoded by Ad5/3-D24-GMCSF on human
monocytes, we infected human melanoma SK-MEL-28 cells with 10 multiplicity of
infection (MOI) of either Ad5/3-D24 or Ad5/3-D24-GMCSF, or left the cells
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uninfected. After 48 h, the cells were collected and the supernatants were filtered
with 0.22 µm filter (Millex® - GP, Millipore, Ireland) and with 100K spin filter
(Amicon® Ultra 0.5 ml, Millipore, Ireland). Human peripheral blood-derived
monocytes were isolated from leukocyte-rich buffy coats from three different
healthy blood donors (The Finnish Red Cross Blood Transfusion Service). Details
on the protocol are described in the original publication (study III) and references.
Monocytes were stimulated 24 h post-plating with filtered supernatant from Ad5/3-
D24-GMCSF-infected or Ad5/3-D24-infected SK-MEL-28 melanoma cells. GM
(Macrophage-SFM media, Gibco) was changed every other day. Commercial
human recombinant GM-CSF (10 ng/ml, Immunotools), supernatant from
uninfected SK-MEL-28 cells, Ad5/3-D24-GMCSF and Ad5/3-D24 viruses were
used as controls. Four and seven days post-stimulation, we extracted RNA using
RNeasy Mini Kit, and QIAcube (Qiagen), including a DNase digestion with
RNase-free DNase set (Qiagen). cDNA was synthesized using High Capacity
cDNA Reverse Transcription kit (Applied Biosystems). Real-time PCR analysis of
PU.1, FCGR1A, CD163 and GAPDH genes  was  performed  using  FAST
SYBRgreen master mix and 7500 FAST Real-Time PCR system (Applied
Biosystems). SYBRgreen oligonucleotides and primers for analysis of M-CSF,
GM-CSF and IFIT2 expression are described in the original publication (study III).
Comparative threshold-cycles (Ct) method was used to calculate relative
expression of target genes, after normalization to GAPDH.
3.4.5 Immunogenicity of cell death (II)
In study II, immunogenic cell death was assessed by measuring the exposure of
calreticulin on cell surface, and the amount of adenosine triphosphate (ATP) and
high-mobility group box 1 (HMGB1) protein released in the supernatant (Diaconu
et al., 2012). Cells were seeded on 6-well plates at 500 000 cells/well and infected
with 100-1000 VP/cell of virus (depending on the cell line) and/or treated with
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chemotherapeutic (doxorubicin and 4-hydroperoxyifosfamide). Calreticulin
exposure on cell surface was measured 12h post-infection, after incubation with
anti-calreticulin antibody (Abcam, Cambridge, UK) and detection with Alexa-
Fluor® 488 conjugated secondary antibody (Invitrogen, San Diego, CA). BD
Accuri C6 (BD Biosciences, San Jose, CA) was used for flow cytometric analyses.
For ATP and HMGB1 analyses, cell culture supernatants were collected 24 or 48 h
post virus and/or chemotherapy treatment, and analyzed with ATP Determination
Kit (Molecular Probes, Invitrogen) and HMGB1 ELISA Kit (IBL International,
Hamburg, Germany).
3.5 Preclinical in vivo studies
Animal protocols were reviewed and approved by the Experimental Animal
Committee of the University of Helsinki and the Provincial Government of
Southern Finland. All animals were quarantined for at least one week, and their
health status was monitored daily. Animals were euthanized according to local
animal care rules and to humane end-point guidelines. Mice were anesthetized prior
to any procedures either in isoflurane gas or with 100 µl (i.p.) of dexmedetomidine
(Dexdomitor®, Orion Pharma, Espoo, Finland) and ketamine (Ketalar®, Pfizer,
Helsinki, Finland) mix: 2 ml Ketalar® (50 mg/ml) + 1 ml Dexdomitor® (0,5
mg/ml) + 7 ml 0.9 % NaCl. After procedures, the sedative effects were reversed
with 50 µl (i.p.) of atipamezole (Antisedan® 5 mg/ml, Orion Pharma), diluted 1:10
in NaCl. Hamsters were anesthetized with 250 µl (i.p.) of ketamine –
dexmedetomidine mix: 50 mg/kg Ketalar® + 150 µg/kg Dexdomitor®.
3.5.1 Immunodeficient animal models (I-IV)
Female Nude/NMRI mice (3-4 weeks old) were provided by Harlan Laboratories
(Indianapolis, IN, USA). In study I, mice were injected with 5 million SK-LMS-1,
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HT-1080, RD or SW872 cells subcutaneously in both flanks. When tumors reached
the size of approximately 5 mm diameter, viruses (Ad5/3-D24-GMCSF, Ad5/3-
D24 or Ad5wt) diluted in 0.9% NaCl were injected intratumorally at 7 x 109
VP/tumor (2 tumors/mouse) on days 1, 4, 8 and 15. NaCl 0.9% was used as mock
treatment. In study II, mice were injected with 5 million HT-1080 cells into both
flanks, and treated with intratumoral injections of Ad5/3-D24-GMCSF (1 x 108
VP/tumor injected on days 1, 4, 8 and 15), intraperitoneal injections of doxorubicin
(2 mg/kg injected on days 1, 8 and 15), or a combination of both. In study III, mice
received 5 million SK-MEL-28 cells subcutaneously into both flanks. Tumors were
treated with viruses (Ad5/3-D24-GMCSF, Ad5/3-D24, Ad5wt or Ad5/3luc1)
injected intratumorally at 7 x 109 VP/tumor (2 tumors/mouse) on days 1, 4, 8 and
15. Concomitant low-dose CP (20 mg/kg in saline) was injected intraperitoneally
the day after the first virus injection and every 3 days thereafter (Koski et al., 2010,
Liikanen et al., 2013). In study IV, MDA-MB-436 cells (5 five million cells/tumor)
were injected orthotopically in two different mammary fat pad sites. Mice were
randomized into 9 groups and viruses (Ad5/3-D24-GMCSF, Ad5/3-D24, Ad5wt or
Ad5/3luc1) were injected at 7 x 109 VP/tumor on days 1, 4, 8, 15, 29 and 43.
Concomitant low-dose CP was administered as in study III. In all the studies, width
and length of the tumors were measured every 2-3 days with digital calipers, and
tumor volumes were calculated using the formula “0.5 x length x width2”.
3.5.2 Immunocompetent animal models (I, II)
Male Syrian hamsters (Mesocricetus auratus) were purchased from Harlan
Laboratories at 5–6 weeks of age. In study I, hamsters were injected
subcutaneously at four different sites with 5 million DDT1-MF2 cells/site and
randomized into 12 groups. Ten groups of animals were treated intratumorally with
Ad5/3-D24-GMCSF, Ad5/3-D24 or Ad5/3luc1 at three different doses: low (2.1 x
108 VP/tumor), medium (2.1 x 109 VP/tumor) or high dose (2.1 x 1010 VP/tumor),
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or mock-treated with 0.9% NaCl. Hamsters received a single injection of the
indicated viruses on day 1. Two groups of animals received multiple injections,
either of 0.9% NaCl or of Ad5/3-D24-GMCSF in low dose on days 1, 4 and 8. One
of the four tumors growing in each hamster was left without injection, to see if
intratumoral injection of Ad5/3-D24-GMCSF leads to systemic viral spread and
infection of uninjected tumors. In study II, hamsters received 5 million DDT1-MF2
cells subcutaneously into both flanks. In the first experiment, Ad5/3-D24-GMCSF
was injected at 2.25 x 108 VP/tumor every 3 days. In addition, mice who received a
combination treatment were injected with also doxorubicin (1 mg/kg) and
ifosfamide (30 mg/kg) intraperitoneally every 3 days. In the second experiment,
hamsters received the same amount of virus every other day, and doxorubicin dose
was increased to 1.25 mg/kg, injected intraperitoneally every other day. Ifosfamide
was not used. In study II, to perform mechanistic immunological analyses not
possible in Syrian hamsters for lack of reagents, an immunocompetent mouse
model was used. Female C57BL/6 mice (3-4 weeks old) were purchased from
Harlan Laboratories. Animals were injected with 2.5 million B16-OVA melanoma
cells into both flanks. Mice were treated every 3 days with 4.5 x 109 VP/tumor of
Ad5/3-D24-GMCSF alone, doxorubicin/ifosfamide alone (1 and 30 mg/kg,
respectively) or in combination.
3.5.3 Histological and immunohistological analyses (I, II)
In study I and II, to assess potential local or systemic pathological effects of the
viruses, the tumors and relevant organs (heart, liver, spleen and kidney in both
studies; lung and brain were also collected in study I) were collected and fixed in
10% buffered formalin for 24 h, followed by storage in 70% EtOH. Tissues were
then trimmed and routinely embedded in paraffin wax. Sections (3–5 mm) were
prepared and stained with hematoxylin-eosin (HE) for histological evaluation. In
study I, we also performed immunohistological analyses to evaluate the presence of
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T and B cells/plasma cells in the tumors. Cross-reacting antibodies against CD3
(rabbit anti-human CD3; Dako, Glostrup, Denmark) and CD79a (rat anti-human
CD79acg; Dako) were used.  Analysis was done using the streptavidin peroxidase
method with heat pretreatment (citrate buffer pH 6.0) for antigen retrieval and
diaminobenzidin as chromogen. Details on the protocol are in the original
publication or references.
3.5.4 Quantitative PCR analyses (I, II)
Viral DNA load in tumors (I, II), organs (I), blood clots (I) and serum samples (I)
was measured by qPCR. Tumors and organs were collected following euthanasia
and stored at -80°C. Blood samples were collected into sterile tubes: serum and
blood clots were separated by coagulation at room temperature and centrifugation
at room temperature for 10 min at 1000 rpm. Serum samples were stored at -20oC
and the blood clots at -80oC. Tumor tissues or blood clots (approximately 25 mg)
were digested overnight with proteinase K in tissue lysis buffer ATL (Qiagen). For
serum samples, 6 mL of poly(d)A carrier DNA (Roche) was added to 200 mL of
the diluted serum sample (1:1 of serum and PBS). Total DNA was extracted using
the  QIAamp  DNA  Mini  Kit  (Qiagen)  and  QIAcube  machine,  according  to  the
manufacturer’s instructions. qPCR for the adenoviral E4 gene was performed, and
adenoviral E4 copy number was normalized to the hamster GAPDH gene. Details
on the primers and probes are in the original publication or references.
3.5.5 Flow cytometry (II)
In study II, tumors and spleens from euthanized C57BL/6 mice were passed
through a 40-mm cell strainer and cultured overnight at 37oC. Cell suspensions
were collected the next day, frozen and stored at -140 oC. Flow cytometric analyses
were performed using BD Accuri C6 (BD Biosciences), with the following
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antibodies purchased from BD Biosciences: anti-mouse CD11c FITC (clone HL3),
anti-mouse CD3e APC (clone 145-2C11), anti-mouse CD80 PerCP-CyTM5.5
(clone 16-10A1), anti-mouse CD86 PE (clone GL1) and anti-mouse CD8a PE
(clone 53-6.7).
3.6 Treatment of patients with oncolytic adenoviruses (I, III, IV)
3.6.1 Advanced Therapy Access Program (ATAP)
Between 2007 and 2012, a total of 290 patients with advanced solid tumors
refractory to conventional therapies were treated with 10 different oncolytic
adenoviruses at the Docrates Hospital in Helsinki, Finland, in the context of an
Advanced Therapy Access Program (ATAP). ATAP is not a clinical trial but a
personalized treatment program (Dnro 475/E6/06), with the purpose of offering
experimental therapies to patients with metastatic solid tumors refractory to
conventional treatment modalities. ATAP is operated under the ‘Hospital
Exemption’ clause defined in the Advanced Therapy Directive (EU/1394/2007)
and is regulated by the Finnish Medicines Agency (FIMEA) as determined by the
Directive. ATAP was in compliance with European Union and Finnish
Regulations, and was evaluated by The Gene Technology Board and Medicolegal
Department of the Finnish Ministry of Social Affairs and Health. Patients signed a
written informed consent, to confirm the understanding of the experimental
approach of oncolytic adenovirus treatment instead of clinical trial, and treatments
were administered according to Good Clinical Practice and the Declaration of
Helsinki of World Medical Association, based on Article 35. Each patient was
evaluated before treatment decisions, which were based on individual
characteristics of the patients, tumor type, size and location. The treatment was
offered to patients with solid tumors refractory to conventional therapies,
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progressive disease, WHO performance score ≤3, and no major organ function
deficiencies. The treatment was not offered if patients had organ transplant, brain
metastasis, elevated bilirubin alanine transaminase (ALT) or aspartate transaminase
(AST) (over 3-fold upper limit of normal), HIV or other immunosuppression,
severe thrombocytopenia, or other severe disease or organ malfunction. FIMEA
required the report of treatment results, adverse reactions and overall survival.
Analysis of patient samples for retrospective studies has been approved by Helsinki
University Central Hospital (HUCH) operative ethics committee (HUS
62/13/03/02/2013).
Of the 290 patients treated in ATAP, 115 patients received Ad5/3-D24-GMCSF
during their treatments. Of these, all the patients with chemotherapy-refractory
sarcoma (15/115), melanoma (9/115) and breast cancer (16/115) are included in
this thesis (tot. 40 patients; studies I, III and IV). In addition to Ad5/3-D24-
GMCSF treatments, patients were free to receive other cancer therapies, including
additional virus treatments.
3.6.2 Treatment protocols and follow-up
In ATAP, patients received oncolytic adenoviruses intratumorally into the primary
tumor and/or any injectable metastases. Injections were performed in ultrasound or
CT guidance (10 mL volume injected intratumorally with 10 needle tracts). In case
of intrapleural or intraperitoneal disease, injections were given into the relevant
cavity. In this thesis, all treatments were given with Ad5/3-D24-GMCSF, with
doses of up to 4 x 1011 VP. Patients received Ad5/3-D24-GMCSF as a single
treatment or a serial treatment of three consecutive virus injections at 3-4 week
intervals. Typically, at least one fifth of the dose was given intravenously (as a
2.5 mL bolus after intratumoral injection), to reach uninjectable lesions. To reduce
regulatory T-cells, concurrent low-dose metronomic CP was administered either
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per orally (50 mg daily starting one week before virus treatment), or by a single
intravenous bolus of 100 mg on the day of the virus treatment, or a combination of
these (Cerullo et al., 2011, Koski et al., 2010). Some patients received other
concomitant therapies, such as low-dose pulse temozolomide (100 mg/day
administered according to three different dosing schedules), to induce oncolytic
autophagy (Liikanen et al., 2013), and/or verapamil (200 mg twice daily orally one
day after virus treatment and continued for at least 4 weeks) to enhance virus
replication (Koski et al., 2012). None of these “virus sensitizers” were expected to
yield antitumor efficacy on their own; instead they were used to increase the effects
of the virus.
Patients were monitored for 24 hours in the hospital and 4 weeks as outpatients.
Adverse reactions (AR) were monitored for 28 days and recorded according to
Common Terminology Criteria for Adverse Events (CTCAE) v3.0:
· Grade 1: mild AR
· Grade 2: moderate AR
· Grade 3: severe AR
· Grade 4: life-threatening or disabling AR
· Grade 5: AR leading to death
ARs were further classified as Serious Adverse Events (SAEs) if leading to patient
hospitalization, prolongation of hospitalization, malformation, or death. Pre-
existing symptoms were not listed unless they worsened. Transient
lymphocytopenia in the peripheral blood (frequently observed in association with
oncolytic adenovirus treatments) was not considered as an AR, as there is evidence
indicating possibly redistribution of lymphocytes (i.e. trafficking of lymphocytes to
tumors), thus contributing to treatment efficacy (Reid et al., 2002, Brahmer et al.,
2010, Kanerva et al., 2013, Hemminki et al., 2015).
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3.6.3 Detection of viral DNA in patient serum samples
Total DNA was extracted with QIAamp mini kit (Qiagen, Hilden, Germany) from
serum of patients, whose blood was collected before and after virus treatment.
DNA concentration was measured spectrophotometrically, and analyzed at multiple
timepoints by qPCR, to determine viral titer and signs of viral replication. Details
on primers, probes and protocol are described in the original publications and
references (Cerullo et al., 2010, Koski et al., 2010, Escutenaire et al., 2011).
3.6.4 Neutralizing antibody titer determination
Neutralizing antibody titer was measured from patient serum samples using a non-
replicating adenovirus with the same virus capsid of the virus that the patient had
received as treatment. In case of Ad5/3-D24-GMCSF treatments, Ad5/3luc1 was
used. Details on the protocol are described in the original publication and
references (Cerullo et al., 2010, Koski et al., 2010).
3.6.5 Analysis of treatment efficacy and overall survival
Tumor size was assessed by contrast-enhanced computed tomography (CT),
magnetic resonance imaging (MRI), or [18F]-fluorodeoxyglucose positron
emission tomography with a low resolution CT scan (PET-CT) before treatment
and after a median of 4.5 weeks from the latest virus treatment. In case of a serial
treatment, the radiological evaluation was performed after the third virus injection
(the last of the serial treatment). Maximum tumor diameters were calculated
according to modified Response Evaluation Criteria in Solid Tumors (RECIST)
v1.1 (Eisenhauer et al., 2009, Koski et al., 2013), and/or PET criteria (Koski et al.,
2013), including injected and uninjected lesions. Modified RECIST criteria were:
· Complete Response (CR = tumor completely undetectable after treatment)
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· Partial Response (PR ≥ 30% reduction in the sum of tumor diameters)
· Minor Response (MR = 10-29% reduction in the size of lesions)
· Stable Disease (SD ≤ 9% reduction or < 20% increase)
· Progressive Disease (PD ≥ 20% increase or new lesions)
PET criteria (using summed SUVmax from the 5 most active lesions in the PET
images) were:
· Complete Metabolic Response (CMR = disappearance of all metabolically
active tumors)
· Partial Metabolic Response (PMR ≥ 30% decline in summed SUVmax)
· Minor Metabolic Response (MMR = 10-29% decline in summed SUVmax)
· Stable Metabolic Disease (SMD ≤ 9% reduction or < 30% increase)
· Progressive Metabolic Disease (PMD ≥ 30% increase or new metastatic
lesions with ≥ 2 cm diameter and/or sufficient 18F-FDG uptake)
In study IV, tumor markers were also evaluated when elevated at baseline, by
comparing baseline values to the best or worst response, and using the same
percentages listed above.
Overall survival was calculated both from the day of the first virus treatment and
from the day of the first Ad5/3-D24-GMCSF treatment.
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3.7 Statistics (I-IV)
Statistical analyses were performed using SPSS statistics software version 18-21
(SPSS, Chicago, IL), GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA),
and Microsoft Excel 2007 (Microsoft, Redmond, WA). Two-tailed Student’s t test
for independent samples was used for in vitro data (I-IV) and to assess tumor
volume for nude mice experiment in study III. Type III Tests of Fixed Effects and
repeated measures ANOVA on log-transformed data were used for animal
experiments in study I and II. Mann-Whitney U test with Bonferroni correction was
used  to  assess  tumor  volume  for  nude  mice  experiment  in  study  IV. p values of
<0.05 were considered significant. In study II, therapeutic synergy was assessed
using the fractional tumor volume (FTV) method (Yokoyama et al., 2000, Xu et al.,
2011). The expected FTV (i.e., the product of FTV values for monotherapies) of
the combination therapy is divided by the observed FTV of the combination, and
the obtained ratio indicates the nature of the interaction (ratio >1 indicates synergy
and ratio <1 indicates a less than additive effect). For each experimental group,
FTV is obtained by dividing the mean tumor volume of the experimental group by
the mean tumor volume of the control group. Kaplan–Meier method with Log-
Rank tests was used to process patient survival data (I, III, IV).
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4. RESULTS AND DISCUSSION
4.1 Preclinical in vitro results
4.1.1 Effects of capsid modifications on tumor transduction (I, III)
Serotype 5 adenoviruses have been used most frequently in gene therapy. Because
their primary receptor (coxsackie-adenovirus receptor, CAR) is expressed on
cancer cells at variable and often low levels (Bauerschmitz et al., 2002), the
efficacy of gene therapy vectors based on serotype 5 adenoviruses might be
reduced. To overcome this limitation and to increase gene delivery and antitumor
efficacy, the fiber knob region of Ad5 can be replaced with the Ad3 knob,
enhancing cancer cell transduction and antitumor efficacy in preclinical testing
(Kanerva et al., 2003, Kanerva and Hemminki, 2004). This is associated with high
expression of desmoglein-2 (DSG-2) (Wang et al., 2011), the receptor for serotype
3 adenoviruses, on tumor cells (Kanerva et al., 2002, Tuve et al., 2006).
In this thesis, we assessed the transduction of human sarcoma cell lines and Syrian
hamster sarcoma (Study I) and melanoma cells (Study III) by adenoviruses with
different capsid modifications. As shown also previously (Kanerva et al., 2003),
transduction in human cells was improved with a chimeric 5/3 fiber. In contrast,
transduction of the hamster cells was most efficient with the serotype 5 capsid
(Study I, Fig. 1d; Study III, Suppl. Fig. S2b). Ad3CMV-luciferase failed to
transduce the cell line at any VP number/cell. While human cells are permissive to
human adenoviruses, transduction of Syrian hamster cells is not enhanced by 5/3
chimerism. Syrian hamster cells might express lower levels of the receptor(s)
relevant for Ad5/3 than human cells, or hamster DSG-2 might not allow binding to
the human Ad3 fiber (Trinh et al., 2012). In conclusion, 5/3 chimerism enhanced
the transduction of human but not of hamster cancer cells, suggesting that other
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mechanisms may be responsible for Ad5/3 entry into Syrian hamster cells. Indeed,
Ad5/3 shares only the fiber knob with Ad3, and the length of the fiber shaft may be
a determinant of adenoviral attachment strategy (Ambriovic-Ristov et al., 2003).
4.1.2 Ad5/3-D24-GMCSF in vitro efficacy,  as  single  agent  or  in  combination
with chemotherapy (I-IV)
Preclinical reports with GM-CSF-encoding viruses have indicated promising
antitumor efficacy in the treatment of advanced solid tumors (Cerullo et al., 2010,
Koski et al., 2010, Burke, 2010, Pesonen et al., 2012a). Ad5/3-D24-GMCSF has
shown good tolerability and efficacy in vitro, in animal models and in cancer
patients (Koski et al., 2010, Kanerva et al., 2013). We studied the susceptibility of
human and Syrian hamster cancer cells to oncolysis by Ad5/3-D24-GMCSF. All
the human sarcoma and melanoma cell lines were permissive and susceptible to
Ad5/3-D24-GMCSF (Study  I,  Fig.  1;  Study  III,  Fig.1). Cell-killing efficacy of
Ad5/3-D24-GMCSF was superior to that of Ad5wt and comparable to that of
Ad5/3-D24, as expected, since GM-CSF does not add efficacy in vitro.
Interestingly, in human melanoma pMelL cells which do not express CAR, both
Ad5/3-D24 and Ad5/3-D24-GMCSF viruses induced greater cell killing than
Ad5wt (Study III, Fig. 1g).
In hamster sarcoma cells, despite their permissiveness to Ad5/3-D24-GMCSF
replication (Study I, Suppl. Fig. S1), Ad5wt virus was slightly more effective than
Ad5/3-D24-GMCSF and Ad5/3-D24, while hamster melanoma cells were resistant
to both Ad5/3D24 and wild-type adenoviruses (Study III, Suppl. Fig. S2a), as
previously reported also by others (Zhang et al., 1996). These results suggest that
possible additional mechanisms limit the adenoviral replication-cycle in these
hamster melanoma cells. Certain cell lines from species other than humans support
the full replication cycle of human adenoviruses, although at reduced efficacy
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(Jogler et al., 2006). In rodent and rabbit cells, restriction of productive human
adenovirus replication acts primarily at a post-entry step, and thus, some of the late
steps of replication may be compromised also in Syrian hamsters (Jogler et al.,
2006).
Preclinical and clinical studies have shown that oncolytic viruses can be combined
with conventional anticancer treatments, such as chemotherapy, enhancing the
efficacy of the viral treatment without increasing side effects (Cerullo et al., 2011,
Liikanen et al., 2013, Ottolino-Perry et al., 2010). In our in vitro combination
studies (Study II and IV) we saw an additional cell killing when Ad5/3-D24-
GMCSF was combined with doxorubicin (with or without ifosfamide) in human
and Syrian hamster STS cells (Study II, Fig. 1e, Fig. 4), and with low-dose CP or
4-HP-CP in human TNBC cells (Study IV, Fig. 1). Since CP is a prodrug, and thus
it is not expected to be active in cells in vitro which lack cytochrome P450
enzymes (Sladek, 1972), our result shows that pathways other than liver enzymes
can also activate CP, which is in line with a previous publication (Ginsberg et al.,
1977). In conclusion, Ad5/3-D24-GMCSF was able to enter into and replicate in
human and hamster STS cells, and in human melanoma and breast cancer cells,
with subsequent oncolysis. The addition of chemotherapeutic agents in vitro
resulted in additional cell killing both in human and Syrian hamster STS cells, and
in human TNBC cells. Next, we sought to find out the mechanisms underlying the
combination effect between virus and chemotherapy. Possible reasons could be
related to altered replication kinetics and induction of immunogenic tumor cell
death, as reported also previously (Raki et al., 2005, Liikanen et al., 2013).
61
4.1.3 Adenoviral replication in absence or presence of doxorubicin and/or 4-
hydroperoxyifosfamide (I, II)
Based on our transduction results, to better understand if Syrian hamster is
permissive to replication of 5/3 chimeric viruses, we studied Ad5/3-D24-GMCSF
replication in the Syrian hamster DDT1-MF2 leiomyosarcoma cell line, and the
effect of chemotherapy on adenoviral replication in vitro (Studies I and II). In a
progressive infectivity assay, oncolysis of DDT1-MF2 cells developed overtime,
suggesting productive replication (Study I, Suppl. Fig. S1). The addition of
doxorubicin and 4-hydroperoxyifosfamide led to an increase in adenoviral
replication compared to the virus alone (p = 0.0033; Study II, Fig. 1d). Also in
human STS cells, viral genome copy number was significantly higher in the
presence of doxorubicin in 4 out of 5 analyzed cell lines (Study II, Fig. 4). We
conclude that Ad5/3-D24-GMCSF replicates in Syrian hamster STS cells and that
chemotherapy enhances adenoviral replication, both in human and hamster STS
cells. These results are in line with previous reports suggesting increased viral
replication in the presence of other chemotherapeutic agents such as gemcitabine
(Raki et al., 2005), paclitaxel and docetaxel (Yu et al., 2001), as well as increased
replication of oncolytic measles virus mediated by doxorubicin-induced senescence
(Weiland et al., 2014).
4.1.4 Immunogenicity of cell death induced by the combination of Ad5/3-D24-
GMCSF and chemotherapy (II)
Given the immunogenic properties of doxorubicin and ifosfamide, we studied the
induction of immunogenic cell death (ICD) after infection with Ad5/3-D24-
GMCSF (an intrinsically immunogenic agent) and doxorubicin/4-
hydroperoxyifosfamide in the Syrian hamster DDT1-MF2 leiomyosarcoma cells
(Study II).  The combination of virus with the two chemotherapeutic drugs
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resulted in increased calreticulin exposure in comparison to control cells and a
trend for increase over single agents (Study II, Fig. 1a). Furthermore, the cells
treated with the combination regimen released more HMGB1 in the supernatant,
compared to control cells and single agents (Study II, Fig. 1b), and the amount of
extracellular ATP was significantly higher compared to virus alone (Study II, Fig.
1c). In the human fibrosarcoma cell line HT-1080, the combination of virus and
doxorubicin resulted in significantly increased calreticulin exposure over control
cells and virus alone, and trends for increased amount of released HMGB1 and
ATP (Study II, Suppl. Fig. S2a-c). As a conclusion, the combination of Ad5/3-
D24-GMCSF with chemotherapeutic agents with immunogenic properties
enhances induction of ICD both in human and Syrian hamster STS cells. This is in
line with previous observations of enhanced ICD following combination of Ad5/3-
D24-GMCSF with low-dose CP and temozolomide (Liikanen et al., 2013)
4.2 Preclinical in vivo results
4.2.1 Ad5/3-D24-GMCSF antitumor efficacy in immunodeficient animal
models, as single agent or in combination with chemotherapy (I-IV)
Efficacy studies in vivo using human cells require the use of xenograft models.
This model does not allow the study of GM-CSF-mediated effects, since human
GM-CSF is not bioactive in mice due to species-specificity (Shanafelt et al., 1991).
Despite this limitation, we used the model to confirm the oncolytic in vivo
antitumor potency of Ad5/3-D24-GMCSF (Studies I-IV). As a single agent,
Ad5/3-D24-GMCSF was more effective than mock and Ad5wt-treated animals in a
STS xenograft model (Study I, Fig. 2). The effect of the treatment was enhanced
when the virus was combined with doxorubicin, in the same fibrosarcoma
xenograft model, with improved survival and evidence of synergism (Study II,
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Fig. 5a-c). In studies III and IV, the virus was combined with low-dose CP, in a
melanoma and a TNBC xenografts models. In these models, low-dose CP alone did
not show any effect, while in combination with Ad5/3-D24-GMCSF, led to a
significant enhancement of tumor growth inhibition, compared to CP and virus
only treatments (Study III, Fig. 2a, Suppl. Fig. S1; Study IV, Fig. 2, Suppl. Fig.
S1). In particular, in the melanoma xenograft model, the mice treated with this
combination exhibited complete tumor regression (Study III, Fig. 2a, Suppl. Fig.
S1). As expected, in this model where human GM-CSF is not bioactive, Ad5/3-
D24 was as efficient as Ad5/3-D24-GMCSF, as a single agent and in combination
with low-dose CP (Study III, Fig. 2b, Suppl. Fig. S1; Study IV, Suppl. Fig. S1).
These results obtained from immunodeficient animals (lacking T-cells) suggest that
low-dose CP has possible mechanisms of action other than reduction of regulatory
T-cells (Koski et al., 2010, Cerullo et al., 2011). Indeed, previous publications
report CP as an anti-angiogenic drug able to modify tumor microenvironment,
when administered at low continuous dosage (Man et al., 2002, Wang et al., 2012b,
Loven et al., 2013, Nicolini et al., 2004). In conclusion, efficacy studies in
xenograft models showed superior antitumor potency of Ad5/3-D24-GMCSF over
controls. Furthermore, when chemotherapy was added, the efficacy of the treatment
was improved in all three tumor types, suggesting useful combination effects with
the virus.
4.2.2 Ad5/3-D24-GMCSF antitumor efficacy in immunocompetent animal
models, as single agent or in combination with chemotherapy (I, II)
To study the efficacy of Ad5/3-D24-GMCSF in an immunocompetent animal
model in which also human GM-CSF is bioactive (Cohen et al., 1988, Cerullo et
al., 2010, Koski et al., 2010), we performed two in vivo experiments in Syrian
hamsters, reported also semi-permissive for human adenovirus replication (Thomas
et al., 2006). First, we attempted to study Ad5/3-D24-GMCSF as a single agent, in
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a dose-escalation efficacy study (Study I). Syrian hamsters carrying four DDT1-
MF2 leiomyosarcoma tumors were treated with a single intratumoral injection of
Ad5/3-D24-GMCSF or control viruses (Ad5/3-D24, Ad5/3luc1) at three different
doses: low (2.1 x 108 VP/tumor), medium (2.1 x 109 VP/tumor) or high dose (2.1 x
1010 VP/tumor). To study the effect of a multiple administration of the virus, two
groups of animals received three injections of Ad5/3-D24-GMCSF (or NaCl as
mock treatment) in low dose on days 1, 4 and 8. Doses and treatment days were
selected according to previous studies (Koski et al., 2010) and treatment schedule
of human patients. Treatment with a single injection of medium or high dose of
Ad5/3-D24-GMCSF resulted in statistically significant tumor growth inhibition
compared to mock-treated animals (Study I, Suppl. Fig. S2a), whereas a single
low-dose injection of any viruses resulted in no difference in tumor growth (Study
I, Suppl. Fig. S2b). Similarly, a single injection of medium or high dose of Ad5/3-
D24 resulted in statistically significant slower tumor growth, compared to mock
animals, despite the absence of GM-CSF (Study I, Suppl. Fig. S2c-d). In this
experiment, GM-CSF-expressing virus did not enhance antitumor efficacy, as
measured by tumor growth, in consequence of possible GM-CSF-mediated
inflammatory swelling (Kanerva et al., 2013), which could have affected tumor size
measurements. In contrast to the single low-dose treatment, multiple injections of
Ad5/3-D24-GMCSF in low dose resulted in statistically significant antitumor
activity compared to mock treatment (Study I, Suppl. Fig. S2e,f).
Treatment outcome can benefit from systemic effects, which are important also for
the treatment of metastatic diseases. Intratumorally injected oncolytic viruses could
release virus progeny into the blood, leading to transduction of metastases.
Furthermore, locally administered viruses could induce a systemic antitumor
immune response. To assess if Ad5/3-D24-GMCSF treatment has systemic effects,
we left one of the four tumors in each hamster without virus injection. In Ad5/3-
D24-GMCSF treatments, we observed no difference in the size of injected and
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uninjected tumors (Study I, Fig. 3a). Interestingly, uninjected tumors in Ad5/3-
D24-treated animals grew faster compared to the uninjected tumors in Ad5/3-D24-
GMCSF-treated animals, suggesting GM-CSF-mediated systemic effects (Study I,
Fig. 3a,b). Furthermore, virus genomes were recovered from both injected and
uninjcted tumors, blood clots and cell-free serum, suggesting virus dissemination
into the blood and transduction of metastases (Study I, Fig. 3c,d; Suppl. Fig. S3,
S4). To assess if the presence of virus DNA in uninjected tumors is required for
antitumor effects in distant metastases, we compared the size of uninjected tumors
that contained Ad5/3-D24-GMCSF genomes versus uninjected tumors that did not
contain Ad5/3-D24-GMCSF DNA. We observed no difference, suggesting that
GM-CSF produced by the virus can arouse immunological effects in distant
metastases also without the presence of virus DNA.
GM-CSF systemic concentration is an important aspect, since GM-CSF is known
to cause systemic toxicity and to recruit myeloid-derived suppressor cells (MDSC),
leading to reduction of antitumor immune responses (Serafini et al., 2004). Our
results show the ability of intratumorally injected Ad5/3-D24-GMCSF to reach
distant uninjected tumors (in the same animal) through the blood stream, leading to
systemic effects useful for the treatment of metastatic cancer. However, as
previously shown, intratumoral injections of GM-CSF support local production of
GM-CSF at the tumor site, without increasing systemic concentration to the
“threshold level” above which GM-CSF results in tumor immunosuppression
(Koski et al., 2010). In conclusion, multiple dosing with Ad5/3-D24-GMCSF
emerged as more efficient than a single injection. Furthemore, intratumorally
injected virus can spread to non-injected tumors of the same animal, and virally-
produced GM-CSF can mediate immunological effects in distant metastases.
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To improve the overall treatment outcome, in Study II we evaluated the
combination of Ad5/3-D24-GMCSF with doxorubicin and ifosfamide in the same
immunocompetent Syrian hamster animal model, based on promising in vitro
results (Study II, Fig. 1e). The animals, implanted with DDT1-MF2
leiomyosarcoma cells, received intraperitoneal injection of doxorubicin (1 mg/kg)
and ifosfamide (30 mg/kg) and/or intratumoral injection of Ad5/3-D24-GMCSF
(4.5 x 109 VP/kg) every 3 days. Both single treatments (Ad5/3-D24-GMCSF and
chemotherapy alone) inhibited tumor growth compared to mock-treated animals,
while the combination treatment was the most effective in controlling tumor
growth and improving the survival of the animals (Study II, Fig. 2a,b).
Furthermore, the FTV method to assess combination effects revealed therapeutic
synergy, with an odds ratio > 1 (Study II, Fig. 2c). We also studied the
combination of Ad5/3-D24-GMCSF with doxorubicin without ifosfamide in the
same animal model (Study II, Fig. 3), based on the results of a randomized phase
III trial for patients with advanced STS (van der Graaf et al., 2012) which showed
no additional effects of doxorubicin+ifosfamide treatment compared to doxorubicin
alone. In this experiment, hamsters received intratumoral virus injections (4.5 x 109
VP/kg) and/or intraperitoneal doxorubicin injections (1.25 mg/kg) every other day.
With the increased doses and administration frequency of doxorubicin and virus,
Ad5/3-D24-GMCSF treatment did not result in better antitumor efficacy than the
chemotherapeutic treatment alone. Both doxorubicin alone and the combination
treatment reduced tumor growth significantly compared to mock treatment, but the
difference between the two groups was not significant (Study II, Fig. 3a).
Interestingly, less efficacy was observed when Ad5/3-D24-GMCSF administration
was more frequent (Study  II,  Fig.  3a), probably attributable to inflammatory
swelling in response to adenovirus injection (Reid et al., 2005, Koski et al., 2013),
result obtained also in Study I. The degree of permissivity of Syrian hamsters to
the chimeric 5/3 fiber is not clear. According to our findings (in vitro transduction
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assay and in vivo experiments), Syrian hamsters may be less permissive to 5/3
chimeric viruses than to Ad5wt (Study I and II), and thus it is not optimal for the
evaluation of Ad5/3-D24-GMCSF oncolytic efficiency. We conclude that
combination of virus and chemotherapeutic drugs results into therapeutic synergy
in the Syrian hamster STS model, improving also the survival of the animals.
Of note, apart from the neoplastic process, necrosis and acute hemorrhage in tumor
tissues, none of the hamsters (treated and untreated) exhibited any significant
pathological changes in any of the analyzed normal organs, suggesting lack of local
or systemic pathological effects of the virus treatment (Study I, II).
4.2.3 Effects of chemotherapy on adenoviral replication in vivo (II)
Based on our in vitro results showing significant increase in adenoviral replication
in DDT1-MF2 cells infected with Ad5/3-D24-GMCSF and doxorubicin/4-
hydroperoxyifosfamide (Study II, Fig. 1d), we collected DDT1-MF2 tumors from
Syrian hamsters treated with intratumoral injections of Ad5/3-D24-GMCSF and/or
intraperitoneal injections of doxorubicin, to analyze adenoviral E4 copy number. A
significant increase in copy number was observed in combination-treated tumors
compared to tumors treated with virus alone, suggesting increased adenoviral
replication in the presence of doxorubicin (Study II, Fig. 3b). Similar results were
obtained by previous studies which reported the combination of viruses with
different chemotherapeutic drugs (Raki et al., 2005, Yu et al., 2001, Weiland et al.,
2014). In conclusion, adenoviral replication was increased by the presence of
chemotherapeutic drugs both in vitro and in vivo in Syrian hamster STS tumors
treated with combination regimens.
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4.2.4 In vivo immunological effects of Ad5/3-D24-GMCSF alone or in
combination with chemotherapy (I, II)
Given the potent immunostimulatory capacity of GM-CSF, we studied the
immunological effects of the virus in immunocompetent Syrian hamsters (Study I)
and C57BL/6 mice (Study II). Since GM-CSF has a major role in stimulating DCs,
which can result in T-cell attack on tumors (Dranoff, 2003), in Study I we analyzed
the tumors collected from Syrian hamsters for the degree of T-cell (CD3+) and B
cell/plasma cell (CD79a+) infiltration. We observed a trend for more T-cells in
injected and uninjected tumors of virus-treated animals compared to tumors of
mock-treated animals (Study I, Suppl. Fig. S5a). In particular, the trend was
highest in the animals that were treated with Ad5/3-D24-GMCSF-repeated low-
dose (Study I, Suppl. Fig. S5a, S6). No difference was seen in B-cell and plasma
cell infiltration, which were also often observed in tumor periphery (Study I,
Suppl. Fig. S5b). Some tumors, in particular tumors treated with low-dose Ad5/3-
D24-GMCSF, also displayed heterophil (equivalent of neutrophils in other species)
infiltration, which could be a local effect of GM-CSF (Khajah et al., 2011).
Immunological studies in Syrian hamsters are limited by the lack of reagents.
Because there are currently no antibodies that would allow the study of different T-
cell subsets, our result (obtained with a cross-reacting antibody against CD3) does
not separate between cytotoxic and regulatory T-cells. For this reason, the
mechanistic immunological effects of Ad5/3-D24-GMCSF and
doxorubicin/ifosfamide combination therapy were studied in immunocompetent
C57BL/6 mice carrying B16-OVA melanoma tumors (Study II), with the
limitation that human adenovirus does not induce oncolysis of mouse cells. Tumors
and spleens of mice treated with Ad5/3-D24-GMCSF and/or
doxorubicin/ifosfamide chemotherapy every 3 days were stained with antibodies
against key markers of DC maturation (CD80 and CD86). We observed no
difference in tumor samples between groups, but a statically significant increase in
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DC maturation in spleens of combination-treated mice compared to those treated
with virus only (Study II, Suppl. Fig. S1). We also analyzed CD8+ cytotoxic T-
cell in tumors and spleens, but we saw no significant differences between treatment
groups.
With regard to human immune cells, we showed that GM-CSF encoded by the
virus and produced from infected human melanoma cells, led to differentiation of
human primary monocytes into macrophages (Study III, Fig. 3 and Suppl. Fig.
S3, S4), which is an important step in the induction of immune responses against
the tumor. These results suggest that virally encoded GM-CSF can achieve
important immunological effects (induction of monocyte-macrophage
differentiation, DC maturation, and possible recruitment of immune cells at the
tumor site), but further studies are required to clarify these points.
4.2.5 Mechanisms of synergy between Ad5/3-D24-GMCSF and doxorubicin-
based chemotherapy (II)
In Study II, we concluded that Ad5/3-D24-GMCSF combined with doxorubicin or
doxorubicin plus ifosfamide is an effective treatment modality for STS in a fully
immunocompetent system, with evidence of therapeutic synergy. But what is the
mechanism of synergy between virus and chemotherapy? Our results, obtained
from different animal models (each with its limitations), revealed that:
1) The combination of doxorubicin and ifosfamide is immunogenic (Study II,
Fig. 1a-c). Immunogenicity of cell death is an important aspect for stimulation
of DCs, which can consequently take up tumor-associated antigens (TAAs)
and present them to CD4+ and CD8+ T-cells in the local lymph node, for
activation of adaptive immune response (Smyth et al., 2001). In this context,
the role of Ad5/3-D24-GMCSF replication is to mediate tumor cell lysis, with
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consequent release of TAAs and increase of “danger signals” at the tumor site.
In the meanwhile, GM-CSF produced by the virus further recruits and activates
DCs.
2) Ifosfamide is an alkylating agent, analog of cyclophosphamide. Like
cyclophosphamide, it can downregulate circulating regulatory T-cells in
immunocompetent hosts (Study II, Fig. 2), with following suppression of their
inhibitory functions on cytotoxic T-cells and NK- cells (Ghiringhelli et al.,
2007). Since tumors recruit immunosuppressive regulatory T-cells to evade
antitumor T-cell responses, the use of ifosfamide and cyclophosphamide in
cancer therapy can lead to a restoration of peripheral T-cell proliferation.
When combined with oncolytic adenovirus treatment, cyclophosphamide (and
ifosfamide) mediates similar effects (Koski et al., 2010, Cerullo et al., 2011).
3)  Doxorubicin enhances adenovirus replication (Study II, Fig. 3,4), particularly
in human cells fully permissive to chimeric 5/3 adenoviruses (Study II,  Fig.
4). Increased virus replication leads to the immunological events described in
point number 1, resulting in an adaptive immune response.
4.3 Clinical results
Based on previous promising published results (Koski et al., 2010, Liikanen et al.,
2013, Kanerva et al., 2013), we hypothesized that treatments with Ad5/3-D24-
GMCSF could particularly benefit patients with advanced sarcoma, melanoma and
breast cancer. To corroborate this hypothesis, using registry research techniques,
we collected the available preliminary human data from the ATAP for each specific
tumor type, in terms of safety, biological virus activity, possible signs of efficacy
and overall survival.
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4.3.1 Characteristics of patients and treatments (I, III, IV)
In Studies I, III and IV, 15 patients with chemotherapy-refractory STS (13/15)
and primary bone sarcomas (2/15), 9 patients with advanced melanoma and 16 with
late stage breast cancer, respectively, received treatments with Ad5/3-D24-
GMCSF. Of the 16 patients with breast cancer, 4 had a TNBC. Patients received
single injections of Ad5/3-D24-GMCSF (single treatment) and/or 3 injections with
Ad5/3-D24-GMCSF within 10 weeks (serial treatment). In some of the serial
treatments, Ad5/3-D24-GMCSF was one of the viruses (out of 3) included in the
treatment. In ATAP, in addition to Ad5/3-D24-GMCSF treatments, patients were
free to receive other cancer therapies, including additional virus treatments. Details
on patients and treatments are available in Study I, Suppl. Materials and Suppl.
Table S1; Study III, Suppl. Materials and Suppl. Table S1, Study IV, Suppl.
Materials and Suppl. Table S1.
4.3.2 Safety of treatments and adverse reactions (I, III, IV)
Adverse reactions were monitored and recorded in every patient who was treated in
ATAP. Ad5/3-D24-GMCSF treatments were overall well-tolerated, with mostly
grade 1-2 adverse reactions (fever, fatigue, nausea, flu-like symptoms, pain and
hematological disturbances). Grade 3 ARs were reported in 5/15 sarcoma patients
(Study I, Table 1), 3/9 melanoma patients (Study III, Suppl. Table S2), and 3/16
breast cancer patients (Study IV, Suppl. Table S2), but none were classified as a
SAE. Grade 4 ARs were encountered in 1/15 sarcoma patients, 1/9 melanoma
patients, and 1/16 breast cancer patients. Of these, only the grade 4
thrombocytopenia reported in sarcoma patient S281 was classified as SAE, since
the patient was hospitalized for a thrombocyte infusion 4 weeks after the last
Ad5/3-D24-GMCSF treatment. Of note, the patient had also received radiotherapy
and dexamethasone which may also have contributed to the low thrombocyte
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number. Grade 4 dyspnea and pericardium/pleural fluid reported in melanoma
patient I266, and grade 4 ketoacidosis reported in breast cancer patient R317 were
caused respectively by disease progression and pre-existing diabetes. Transient
lymphopenia in the peripheral blood was observed in almost all the patients. This is
not unexpected, since viral infections are known to reduce lymphocyte numbers in
blood (Wen et al., 2011). Thus, this phenomenon can be frequently encountered
also in association with oncolytic virus treatments, and likely to reflect
redistribution of lymphocytes from blood to the sites of infection (Reid et al., 2002,
Brahmer et al., 2010, Kanerva et al., 2013, Hemminki et al., 2015). Further studies
on tumor biopsies are required to determine the relevance of this phenomenon.
4.3.3 Neutralizing antibody responses and virus titers in patient serum after
treatment (I, III, IV)
To study the activity of the virus in human patients, we assessed neutralizing
antibody titer and the presence of adenovirus genomes in serum before and after
viral treatments. At baseline, neutralizing antibodies against Ad5/3 were detectable
in low to intermediate range in 9/12 evaluable sarcoma patients (Study I, Table 2),
3/6 melanoma patients (Study III, Table 1), and 4/5 evaluable breast cancer
patients (Study IV, Suppl. Table S3). After treatment, the titer increased or
remained stable in all the evaluable patients. Prolonged presence of viral genomes
in serum is indicative of virus replication, since injected virus is rapidly cleared
from the blood stream (Galanis et al., 2005). Overall, there was no viral DNA in
serum at baseline, while we frequently observed measurable viral DNA levels at
one day after treatment, and increase of the viral DNA load beyond day 2,
suggesting virus replication (Study I, Table 2; Study III, Table 1; Study IV,
Suppl. Table S3). We did not observe a clear correlation between neutralizing
antibody titers and viral DNA in serum, in line with other reports (Galanis et al.,
2005, Nemunaitis et al., 2001).
73
4.3.4 Clinical responses and survival (I, III, IV)
The regulatory agency FIMEA required reporting data on safety, viral kinetics and
treatment responses obtained from ATAP. Thus, we reported possible signs of
efficacy of Ad5/3-D24-GMCSF treatments in sarcoma, melanoma and breast
cancer patients. In Study I, the tumors of 9/15 patients were imaged with CT:
tumors size after treatment was compared to pre-treatment CT scans, and the
response was evaluated according to modified RECIST 1.1. criteria. A total of 12
evaluations were performed (3 patients were evaluated after each Ad5/3-D24-
GMCSF injection), and treatments resulted in stable disease or better in 8/12
evaluations (Study  I,  Table  2). In Study III, 4/9 patients were evaluable for
treatment response, resulting in disease control in 3/4 patients (Study III, Table 1).
In Study IV, 13/16 patients were evaluable according to modified RECIST 1.1.
and/or PET criteria. Overall, 1/14 had a MR/PMR, 2/14 a SD, 10/14 a PD/PMD
(Study IV, Table 1 and Fig. 3a,b). Furthermore, serum breast cancer antigen 15-3
(Ca15-3) and carcinoembryonic antigen (CEA) levels were also followed-up as
possible indicators of treatment response for 13 patients whom had had elevated
marker levels before the start of the virus treatment (Study IV, Table 1 and Fig.
3c): 1/13 patient had a CR (with CEA), 1/13 had a PR (with Ca15-3), 5/13 had a
MR (3 with Ca15-3 and 2 with CEA), 1/13 a SD (with Ca15-3) and 5/13 a PD
(with Ca15-3). In one patient (R170), both Ca15-3 and CEA were measured, and
different responses were obtained (129% increase of Ca15-3 and 10% reduction of
CEA marker levels) (Study IV, Table 1 and Fig. 3c). TNBC patients (4/16)
showed PD after treatment, underlining the aggressive nature of this breast cancer
subgroup. Of note, one of these patients (R328) showed a 22% reduction in the size
of injected lesions and 70% decrease of tumor marker CEA, suggesting antitumor
activity of the virus. However, in the final RECIST analysis the patient showed
PMD, due to two new metastases (Study IV, Table 1 and Fig. 3).
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Overall survival data was also collected and, a total of 4 patients (one sarcoma
patient, 2 melanoma patients and one breast cancer patient) were still alive at the
time of submitting the original manuscripts (Figure 2). At the time of writing this
thesis, survival was updated: the sarcoma patient, one melanoma patient and the
breast cancer patient are still alive, over 6, 6.5 and 4 years after treatment
respectively, while there is no information available regarding the second
melanoma patient. Median survival was 170, 51 and 233 days after the first Ad5/3-
D24-GMCSF treatment, respectively of all treated sarcoma (Study I, Fig. 4),
melanoma (Study III, Suppl. Fig. S5) and breast cancer patients (Study IV,
Suppl. Fig. S2).
Figure 2. Overall survival of Ad5/3-D24-GMCSF-treated sarcoma, melanoma
and breast cancer patients. Survival after the first treatment with Ad5/3-D24-
GMCSF virus was analyzed by Kaplan-Meier method. Four patients (one sarcoma,
two melanoma and one breast cancer patient) were alive at the time of submitting
the original manuscripts. Sarcoma, N = 15; Melanoma, N = 9; Breast cancer, N =
16.
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5. SUMMARY AND CONCLUSIONS
In this thesis, we investigated Ad5/3-D24-GMCSF for the treatment of sarcoma,
melanoma and breast cancer, and we explored methods for improving the overall
antitumor efficacy of the virus by combining oncolytic virus therapy with
commonly used chemotherapeutic agents. We summarized and analyzed data from
cancer patients treated in ATAP, providing preliminary information useful for
optimal designing of potential future clinical trials. Our results are in line with
previous publications on Ad5/3-D24-GMCSF, suggesting that this virus is a
promising agent for treatment of advanced solid tumors.
With regard to in vitro results,  in  study  I  and  III,  we  demonstrated  that  5/3
chimerism enhanced the viral transduction of human sarcoma cell lines but not of
hamster sarcoma and melanoma cells. These results, together with previous
publications, suggest that Syrian hamsters are semi-permissive to human serotype 5
adenoviruses, but not at the same degree to 5/3 chimeric adenoviruses.
In vivo, we studied Ad5/3-D24-GMCSF as a single agent (study I) and in
combination with doxorubicin and ifosfamide (study II), in the only hamster
sarcoma model currently available. In study I, due to rapid tumor growth,
assessment of tumor size did not indicate antitumor efficacy. Nevertheless, in study
II we observed an efficient tumor-growth control when the virus was combined
with doxorubicin with or without ifosfamide, and we demonstrated increased
adenoviral replication in the presence of chemotherapy.
Based on previous studies showing advantages in using low-dose metronomic
chemotherapy in combination with oncolytic immunotherapy, we studied the
combination of Ad5/3-D24-GMCSF with low-dose CP in melanoma and breast
cancer preclinical models (studies III and IV), and we observed improved
antitumor efficacy in the combination treatment compared to single agents.
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Our in vivo results in study I showed the ability of intratumorally injected Ad5/3-
D24-GMCSF to reach distant uninjected tumors (in the same animal) through the
blood stream, leading to systemic effects useful for the treatment of metastatic
cancer. In addition, in study III we demonstrated that virally encoded GM-CSF,
produced from tumor cells in vitro, can stimulate differentiation of human primary
monocytes into macrophages, important for induction of immune responses.
Finally, our preliminary data from cancer patients treated in ATAP showed
promising results regarding safety, signs of possible treatment benefits and patient
survival. However, these results should be interpreted with caution as only clinical
trials may ultimately determine if the safety and efficacy features obtained in vitro
and in vivo experiments on animal models are retained in humans. Of note, the first
phase I study of Ad5/3-D24-GMCSF in late-stage refractory cancer patients was
recently successfully completed by Oncos Therapeutics Ltd., proving safety of the
treatment and induction of innate, adaptive and antitumor immune responses, with
stabilization of disease in 40% of evaluable patients after 3 months (Oncos
Therapeutics Ltd., unpublished).
In conclusion, oncolytic immunotherapy combined with low-dose chemotherapy is
a promising approach for treatment of cancer, where the antitumor effects of the
virus overlap with the beneficial effects of low-dose chemotherapy, leading to
oncolysis of cancer cells, strong pro-immunogenic signals, induction of innate and
adaptive immune responses, while low-dose chemotherapy enhances viral
replication, reduces tumor immunosuppression, and modifies tumor
microenvironment. Phase I/II trials studying combination regimens including
Ad5/3-D24-GMCSF are in the planning stages.
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6. FUTURE PROSPECTS
Combination therapies
The rationale for combination therapies is to use treatments that work by different
mechanisms, thereby increasing the chance of killing more cancer cells and to
prevent the emergence of resistance. For some tumors, the best approach is a
combination of surgery, radiotherapy, and chemotherapy. Radiotherapy and
chemotherapy can be administered before surgery to shrink a tumor, thus
improving the chance of complete surgical removal. If applied after surgery,
radiotherapy and low-dose chemotherapy help to destroy remaining cancer cells
and those that have spread to distant sites. While increasing the likelihood of a
cure, combination therapies can also cause more side effects, and thus the goal is to
find appropriate combination of treatments to achieve synergistic killing while
avoiding additive toxicity (Al-Lazikani et al., 2012).
The rise of new treatment options, including oncolytic virotherapy, cancer
immunotherapy and targeted therapy has increased the number of appealing
combination approaches, mainly aiming at inhibiting molecular pathways that are
crucial for tumor growth or destroying cancer cells via oncolysis, while modulating
and stimulating host antitumor immune responses (Vanneman and Dranoff, 2012).
Several clinical trials are underway to evaluate the optimal sequencing of different
therapies (ClinicalTrials.gov). With regard to oncolytic virotherapy, oncolytic
viruses have been combined with standard radiation therapy and chemotherapeutic
agents, as well as with novel biologic therapies, including immunotherapy
(Ottolino-Perry et al., 2010). With the discovery that radiotherapy enhances viral
oncolysis, and that certain viral proteins sensitize cells to radiation therapy, the
combination of these two treatments has been widely studied, with promising
synergistic antitumor effects in preclinical models (Ottolino-Perry et al., 2010).
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Oncolytic viruses have been investigated in combination with a multitude of
standard chemotherapeutics with different mechanisms of action. Combination of
oncolytic virotherapy with cyclophosphamide, doxorubicin and ifosfamide are
described in this thesis. Other combination regimens which have been evaluated
include cisplatin, 5-fluorouracil, paclitaxel, docetaxel, rapamycin (Ottolino-Perry et
al., 2010), and other alkylating agents such as temozolomide (Liikanen et al.,
2013).
With the idea that oncolytic viruses exert their effects through both direct lysis of
tumor cells and through induction of an immune response, researchers have started
to explore strategies to enhance viral-induced antitumoral immunity. Among these,
the insertion of immunostimulatory molecules such as GM-CSF in the virus
genome has been described in section 1.8. Furthermore, an emerging strategy to
enhance tumor killing is the combination of oncolytic viruses with adoptive cell
therapy. In this setting, viral oncolysis may be able to enhance the efficacious
effects of adoptively transferred T cells.
In summary, the future of cancer treatment is moving towards new combination
treatments, including oncolytic virotherapy, standard therapies (chemotherapy,
radiation therapy), and novel immunotherapeutics, aiming both at understanding
the interplay between the agents of choice and providing the best possible clinical
outcome. As forms of therapy such as checkpoint-inhibiting antibodies, targeted
therapy and adoptive T-cell therapy are gaining more and more attention during the
years, it is easy to envision many other combination strategies which may
ultimately reach standard care in the treatment of many advanced tumors.
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